Document:

EX-10.14

 Exhibit 10.14 

Confidential Treatment Requested Evelo Biosciences, Inc. 

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 

PATENT LICENSE AGREEMENT 

This patent license agreement (“Agreement”) is by and between Mayo Foundation for Medical Education and Research, a
Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (“MAYO”), and Evelo Biosciences, Inc. (“COMPANY”), a Delaware corporation, having a place of business at 620 Memorial Drive,
Suite 200 West, Cambridge, Massachusetts 02139, each a “Party,” and collectively “Parties”. 
 WHEREAS, MAYO desires to
make its intellectual and tangible property rights available for the development and commercialization of products, methods and processes for public use and benefit; 

WHEREAS, COMPANY represents itself as being knowledgeable in developing and commercializing therapeutic technologies based on oral
administration of bacteria; and 
 WHEREAS, MAYO is willing to grant and COMPANY is willing to accept an exclusive license under such rights
for the purpose of developing such technology. 
 NOW THEREFORE, in consideration of the foregoing and the terms and conditions set forth
below, the Parties hereby agree as follows: 
 Article 1.00 – Definitions 

For purposes of this Agreement, the terms defined in this Article will have the meaning specified and will be applicable both to the singular and plural
forms: 
 1.01 For MAYO, “Affiliate”: any corporation or other entity within the same “controlled group of corporations”
as MAYO or its parent MAYO Clinic. For purposes of this definition, the term “controlled group of corporations” will have the same definition as Section 1563 of the Internal Revenue Code as of November 10, 1998, but will include
corporations or other entities which if not a stock corporation, more than fifty percent (50%) of the board of directors or other governing body of such corporation or other entity is controlled by a corporation within the controlled group of
corporations of MAYO or Mayo Clinic. MAYO’s Affiliates include, but are not limited to: Mayo Clinic; Mayo Collaborative Services, LLC; Mayo Clinic Hospital, Rochester; Mayo Clinic Florida; Mayo Clinic Arizona; and its Mayo Clinic Health System
entities. 
 For COMPANY, “Affiliate”: any corporation or other entity that controls, is controlled by, or is under common control with,
COMPANY. For purposes of this definition, “control” means ownership of: (a) at least fifty percent (50%) or the maximum percentage, if less than fifty percent (50%), as allowed by applicable law, of the outstanding voting securities
of such entity; or (b) at least fifty percent (50%) of the decision-making authority of such entity. 
 1.02 “Confidential
Information”: all proprietary unpublished or nonpublic information or materials including, but not limited to, written, oral or virtually presented information and such items as electronic media products, trade secrets, financial
information, equipment, databases 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 2
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 and the like provided by one Party to the other under this Agreement, or which is observed by a Party while
on the other Party’s premises. Confidential Information does not include any information or material that receiving party evidences is: (a) already known to the receiving party at the time of disclosure (other than from the disclosing
party); (b) publicly known other than through acts or omissions of the receiving party; (c) disclosed to the receiving party by a third party who was not and is not under any obligation of confidentiality; or (d) independently developed by
employees of the receiving party without knowledge of or access to the Confidential Information. 
 1.03 “Effective Date”:
August 6, 2017. 
 1.04 “Field”: All uses 

1.05 “Know-How”: research and development information, materials, technical data, unpatented
inventions, trade secrets, know-how and supportive information of Joseph A. Murray, M.D., Eric V. Marietta, Ph.D., Susan H. Barton, M.D., Veena Taneja, Ph.D. and Ashutosh Mangalam, Ph.D., owned and controlled
by MAYO as of the Effective Date, to the extent it is necessary for the development or manufacture of a Licensed Product ([***]). For clarity, “materials” herein shall not mean Licensed Materials defined herein. 

1.06 “Licensed Product”: any product or process that: (a) incorporates a composition, or is made by a method, or that entails use
of a method or which infringes an issued claim of the Patent Rights, or that would infringe but for the exception in 35 U.S.C. §271(e)(1), or similar exception in the United States or other countries, or that is covered by a Valid Claim of the
Licensed Patents, or (b) incorporates, utilizes, or is derived from the Know-How or Licensed Materials. 

1.07 “Licensed Materials”: means Prevotella histicola strain B-50329 and any progeny and
derivatives thereof. 
 1.08 “Net Sales”: shall mean the amounts invoiced from the sale of Licensed Product by COMPANY, its Affiliates or a
Sublicensee to any third parties, in accordance with generally accepted accounting principles, less the following deductions: 
  

	(a)	Allowances and rebates actually paid, granted or accrued, including rejections, damaged or defective goods, returns, recalls, retroactive price reductions, rebates, charge backs and prompt payment and volume discounts,
billing errors, reimbursements or similar payments to wholesalers or other distributors, buying groups health insurance carriers or other institutions, pharmacy benefit management companies, health maintenance organizations or any governmental or
regulatory authority or agency (including their purchasers and/or reimbursers), adjustments from consumer discount programs; and 

  

	(b)	In the event gross sales includes freight, transportation, packing, handling, storage fees, governmental duties relating to sales or taxes and/or insurance charges associated with transportation, such amounts will be
deducted to calculate Net Sales subject to Royalty. When such fees are invoiced separately, these amounts will be excluded from any gross to Net Sales calculations. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 3
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

	(c)	Taxes based on sales when included in gross sales, duties and other governmental charges (including value added tax), but not taxes assessed on income derived from such sales. 

 

	(d)	Any invoiced amounts that are not collected by Company and its Licensed Entities, including bad debts relating to such Licensed Products, provided such deductions for uncollected amounts or bad debts may not exceed
[***] of Net Sales in any one year. Company will provide Mayo with documentation upon request of such write-offs of uncollected amounts or bad debts. 

Net Sales accrues with the first of delivery or invoice. 
 In
the event that a Licensed Product is sold in combination with another product that is not a Licensed Product (“Combination Product”), Net Sales, for purposes of royalty payments on the Combination Product, shall be calculated by
multiplying the Net Sales on sale of that combination by the fraction A/B, where A is the gross selling price of the Licensed Product sold separately and B is the gross selling price of the Combination Product. In the event that no such separate
sales are made by the COMPANY, Net Sales for royalty determination shall be calculated by multiplying Net Sales of the combination by the fraction C/(C+D) where C is the fully allocated cost of the Licensed Product and D is the fully allocated cost
of other components, such standard costs being determined using the COMPANY’s standard accounting procedures. 
 For the avoidance of doubt, Net Sales
shall not include sales by Company to its Affiliates or a Sublicensee for resale, provided that if Company sells a Licensed Product to an Affiliate or a Sublicensee for resale, Net Sales shall include the amounts invoiced by such Affiliate or
Sublicensee, to third parties on the resale of such Licensed Product subject to the deductions above. 
 1.09
“Non-commercial Research Purpose”: means the use of Licensed Patents or Licensed Material or both for academic research, education, or other not-for-profit scholarly purposes which are undertaken at a non-profit or government institution. For clarity, Non-Commercial
Research Purposes excludes use in humans. 
 1.10 “Patent Rights”: means, to the extent owned and/or controlled by Mayo:
(i) the patents and patent applications listed on Schedule A attached hereto, including all divisions, continuations, foreign counterparts, and any patents which may issue from such patent applications and any reexamination, reissues,
substitutions, extensions of or to or supplementary protection certificates referencing any such patents or patent applications; and (ii) any claims in
continuations-in-part of any of the foregoing to the extent such claims are fully supported under 35 U.S.C. §112 by the patents and/or patent applications in
(i) above. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 4
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 1.11 “Sublicensee”: any third party or any Affiliate to whom COMPANY has conveyed rights or
the forbearance of suit under the Patent Rights, Know-How or Licensed Materials. 
 1.12 “Term”:
begins on the Effective Date and ends, subject to Article 10 (Term and Termination), upon the date of the last to expire of the Patent Rights, unless the Know-How or Licensed Materials are still in use, or
were used such that Section 3.04 (Earned Royalties) and Article 4 (Accounting and Reports) still apply, in which case the Term shall end upon the date of the satisfaction of these provisions. 

1.13 “Territory”: worldwide. 
 1.14
“Valid Claim”: A claim of (a) a pending patent application within the Patent Rights that has not been pending for more than ten (10) years from its earliest priority date, or (b) an issued claim of any unexpired Patent
Rights or a claim of any pending Patent Rights that have not been held unenforceable, unpatentable, or invalid by a decision of a court or governmental body of competent jurisdiction in a ruling that is unappealable or unappealed within the time
allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

Article 2.00 - Grant of Rights 
 2.0l
GRANT. Subject to the terms and conditions of this Agreement, MAYO grants to COMPANY: (a) an exclusive license with the right to sublicense, within the Field and Territory, under the Patent Rights to make, have made, use,
offer for sale, sell, and import Licensed Products; and (b) an exclusive license, with the right to sublicense, within the Field and Territory, to use the Licensed Materials to develop, make, have made, use, offer for sale, sell, and
import Licensed Products; and (c) a nonexclusive license within the Field and Territory, to use the Know-How to develop, make, have made, use, offer for sale, sell, and import Licensed Products. 

To facilitate the practice of the license granted to COMPANY, during the [***] following the last signature hereto, MAYO will deliver to
COMPANY the Licensed Materials and provide physical and electronic documents embodying the Know How. In addition, MAYO shall provide reasonable access to knowledgeable personnel to transfer Know-How or
Licensed Materials to COMPANY and enable its use by the COMPANY, but in no event shall MAYO be required to provide any Know-How or Licensed Materials in tangible form if it does not exist in tangible form as
of the Effective Date, and in no event shall MAYO be required to provide more than forty-eight (48) hours of service of such access.  
 2.02
RESERVATION OF RIGHTS. COMPANY acknowledges that the inventions claimed in the Patent Rights were made with funds provided by the U.S. Government. All rights granted to COMPANY herein are subject to: (a) the rights and obligations to and
requirements of the U.S. government set forth in 35 U.S.C. §§200 et al., 37 C.F.R. Part 401 et al. (“Bayh-Dole Act”); and (b) MAYO’s and its Affiliates’ reserved, irrevocable, noncommercial, internal right to
practice and have practiced the Patent Rights and Licensed Material in connection with MAYO’s 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 5
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 
and its Affiliates’ Non-commercial Research Purpose, including MAYO’s reference laboratory, Mayo Collaborative Services, LLC, and Mayo Clinic
Care Network. COMPANY agrees to comply with the provisions of the Bayh-Dole Act, including promptly providing to MAYO with information requested to enable MAYO to meet its compliance requirements and substantially manufacturing Licensed Product in
the U.S to the extent required by 35 U.S.C. § 204. For clarity, Non-commercial Research Purposes excludes use in humans.  

2.03 NO OTHER RIGHTS GRANTED. This Agreement does not grant any right, title or interest in or to any tangible or intangible property right of MAYO or
its Affiliates, including any improvements thereon, or to any Patent Rights or Know-How or Licensed Materials outside the Field or Territory that is not expressly stated in Section 2.01 (Grant). All such
rights, titles and interests are expressly reserved by MAYO and COMPANY agrees that in no event will this Agreement be construed as a sale, an assignment or an implied license by MAYO or its Affiliates to COMPANY of any such tangible or intangible
property rights. 
 2.04 SUBLICENSES. Any sublicense by COMPANY shall be to a Sublicensee that agrees in writing to be bound by substantially the
same terms and conditions of this Agreement, excluding financial terms and conditions, or such sublicense shall be null and void. Sublicenses granted by COMPANY hereunder may be transferable, including by further sublicensing, delegatable or
assignable. COMPANY will notify MAYO within [***] after the grant of any Sublicense and provide MAYO with a copy of each sublicense agreement promptly after execution; provided such Sublicense may be redacted to delete any terms that are not
material to compliance with this Agreement. COMPANY is responsible for the performance of all Sublicensees as if such performance were carried out by COMPANY itself, including the payment of any royalties or other payments provided for hereunder
triggered by such Sublicense, regardless of whether the terms of any sublicense require that Sublicensee pay such amounts (such as in a fully paid-up license) to COMPANY or that such amounts be paid by the
Sublicensee directly to MAYO. Each sublicense agreement shall name MAYO as a third party beneficiary; provided, MAYO may only exercise its rights as a third party beneficiary if COMPANY has failed to take steps to correct any breach by a Sublicensee
identified by MAYO. COMPANY shall not grant any fully-paid up, royalty-free or exclusive sublicenses without MAYO’s prior written consent; provided, COMPANY and its Sublicensees may grant sublicenses, with MAYO’s consent, to third parties
performing contract services on behalf of the COMPANY with regard to Licensed Products, e.g, pre-clinical toxicology, manufacturing, clinical trial conduct, etc. In the event of any termination of this
Agreement, any Sublicensee that is not then in material breach of this Agreement shall have the right to retain its sublicense to the Patent Rights, Know How and Licensed Materials by providing notice to MAYO, and in such event any Sublicensee shall
pay directly to MAYO any amounts that would be due to MAYO from COMPANY hereunder for activities conducted by such Sublicensee.      

Article 3.00 - Royalties 
 3.01 UP-FRONT. Within [***] of the Effective Date, COMPANY will make a nonrefundable and noncreditable up-front payment to MAYO of TWO HUNDRED AND TWENTY-FIVE THOUSAND DOLLARS
(US $225,000) for entering into this agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 6
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 3.02 ANNUAL LICENSE MAINTENANCE FEE. Beginning on the second anniversary of the Effective Date and
continuing for the term of this Agreement, COMPANY will pay to MAYO Annual License Maintenances fees on the applicable anniversary of the Effective Date. The first License Maintenance fee payment will be [***]. The Annual License Maintenance fee due
in subsequent years will be [***]. Annual License Maintenance Fees shall not be due in any year where the aggregate amount of the Milestone Fees and Earned Royalties are greater than the applicable Annual License Maintenance Fee. If in any year
during the Term the aggregate amount of the Milestone Fees and Earned Royalties payments made during such year is less than the applicable Annual License Maintenance Fee for such year (a “Shortfall”), then COMPANY shall make an Annual
License Maintenance Fee payment to MAYO in the amount of the Shortfall together with the Milestone Fees and Earned Royalty payment for such year. 

3.03 MILESTONE FEES. COMPANY will pay the following nonrefundable and noncreditable milestone fees to MAYO upon the achievement each of the
following events: 
  

							
	 	  	 EVENT
	  	MILESTONE
PAYMENT	 
	 1
	  	Completion of all GLP toxicology studies necessary to file an IND	  	 	[	***] 
	 2
	  	Commencement of the first human testing of the first Licensed Product (first person, first dose). For clarity, this includes a healthy volunteer study.	  	 	[	***] 
	 3
	  	Completion of the first human testing of the first Licensed Product	  	 	[	***] 
	 4
	  	First patient dosed in the first Phase III Clinical Trial for the first Licensed Product	  	 	[	***] 
	 5
	  	First Commercial Sale (first indication) of Licensed Product in the US	  	 	[	***] 
	 6
	  	BLA approval for a second indication of each Licensed Product by the FDA	  	 	[	***] 
	 7
	  	Upon reaching US Net Sales of Licensed Product of over [***] in one calendar year	  	 	[	***] 

 Each milestone payment shall be payable only once, upon the first occurrence of the corresponding milestone
event, whether achieved by the same or a different Licensed Product than had achieved any other milestone event, except that milestones 5 and 6 are payable not more than twice regardless of how many Licensed Products achieve these milestones. 

As used herein: “Completion” means with respect to milestone 1, completion of the final reports of such studies;
“Commencement” means with respect to milestone 2, first dosing of the first human subject; “Completion” means with respect to milestone 3, lock of the trial database; “Phase III Clinical Trial”
means with respect to milestone 4, a human clinical study 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 7
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 
of a biopharmaceutical product, the design of which is acknowledged by the FDA to be sufficient for such clinical study to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any
replacement thereof), or a similar human clinical study prescribed by the regulatory authority in a country other than the United States of America, the design of which is acknowledged by such regulatory authority to be sufficient for such clinical
study to satisfy the requirements of a pivotal efficacy and safety clinical study; and “First Commercial Sale” means with respect to milestone 5, with respect to a particular Licensed Product, the first commercial sale in an
arms-length transaction of such Product by COMPANY, its Affiliates or its Sublicensees to a Third Party in a country in the Territory after receipt of all regulatory approvals (including without limitation, pricing approvals) for such Licensed
Product in such country, provided, however, that the First Commercial Sale shall not include any transfer of a Licensed Product (i) between or among COMPANY and its Affiliates or its Sublicensees for resale to a Third Party, or
(ii) Licensed Products sold or distributed for clinical studies, compassionate use, named patient programs, sales under a treatment IND, non-registrational studies or other circumstances where any Licensed Product(s) are sold at cost or
supplied without charge, such as promotional samples, or donations (e.g., to not for profit institutions for non-commercial purposes). 

3.04 EARNED ROYALTIES. Subject to Section 3.06, COMPANY shall pay MAYO a nonrefundable and noncreditable tiered royalty of the Net Sales of the
Licensed Product sold by COMPANY, on a Licensed Product by Licensed Product basis (“Earned Royalties”), as follows: 
 (a) Valid Claims
Royalty: In country(ies) in which a Licensed Product is covered by a Valid Claim, COMPANY will pay to MAYO: 
  

	 	i.	[***] on the portion of annual Net Sales that are less than [***] 

  

	 	ii.	[***] on the portion of annual Net Sales that are between [***] 

  

	 	iii.	[***] on the portion of annual Net Sales that are greater than [***] 

 (b) Licensed Material Royalty: In
country(ies) in which a Licensed Product is not covered by a Valid Claim, but includes Licensed Material, COMPANY will pay to MAYO: 
  

	 	i.	[***] on the portion of annual Net Sales that are less than [***] 

  

	 	ii.	[***] on the portion of annual Net Sales that are between [***] 

  

	 	iii.	[***] on the portion of annual Net Sales that are greater than [***] 

 In no event will a Licensed Material
Royalty be due for any Net Sales after fifteen (15) years from the First Commercial Sale of the applicable Licensed Product, on a country-by-country basis and
Licensed Product-by-Licensed Product basis. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 8
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 The Earned Royalties are payable as described in Section 4.01 (Reports and Payments). Licensed Products
transferred to MAYO or its Affiliates are not considered transfers for purposes of determining Net Sales or for calculating Earned Royalties. No Earned Royalties are due MAYO on transfers to MAYO or MAYO Affiliates. Earned Royalties subject to
Section 3.04 (a) above shall terminate on a Licensed Product-by-Licensed Product and
country-by-country basis upon the first date when there is no longer a Valid Claim covering such Licensed Product in the country where such Product is made or sold. 

3.05 ROYALTY STACKING. If COMPANY is a party to a license agreement with any third party under which COMPANY obtains a license for intellectual
property or technology required for the manufacture, use or sale of a Licensed Product and the total royalty due in the aggregate to one or more third parties exceeds [***], then COMPANY may reduce the Earned Royalties due to MAYO pursuant to
Section 3.04 (Earned Royalties) on such Licensed Product (on a product-by-product basis) by [***] of the amounts that are payable to such third party; provided,
however, that in no event will the Earned Royalties otherwise due under Section 3.04 (Earned Royalties) be reduced to less than [***] of the Earned Royalties that would otherwise be payable to MAYO pursuant to Section 3.04 (Earned
Royalties) by operation of the foregoing reduction. For the avoidance of doubt, the Earned Royalties otherwise due under Section 3.04 (Earned Royalties) be not be reduced to more than [***] regardless of the number of additional licenses to
which COMPANY is a party. COMPANY agrees to notify MAYO immediately if COMPANY enters into any additional license(s) with a third party or parties that would affect the Earned Royalty amount received by MAYO. 

3.06 NO MULTIPLE ROYALTIES. If a Licensed Product is covered by more than one patent or patent application within the Patent Rights or a Valid Claim
and uses Licensed Materials, multiple royalties shall not be due. Net Sales shall not be counted for both a Valid Claims Royalty and a Licensed Material Royalty. 

3.07 [***]. MAYO may, at its sole option, purchase the Licensed Product for use within MAYO’s and its Affiliates’ educational research, and
clinical programs in any quantity at [***] offered by COMPANY to any third party for the applicable Licensed Product. The [***] will be determined on each January 1st and will be reported to
MAYO with the report due February 1st pursuant to Section 4.01 (Reports and Payment), and will apply for the 12-month period starting March 1st of such year. COMPANY will also report such sales to MAYO as part of the royalty report described in Section 3.04 (Earned Royalties), however, pursuant to Section 3.04 (Earned
Royalties), no royalties are due on sales to MAYO or MAYO Affiliates. 
 3.08 TAXES. COMPANY is responsible for all taxes, duties, import duties,
assessments and other governmental charges, however designated, which are now or hereafter imposed by any authority on COMPANY: (a) by reason of the performance by MAYO of its obligations under this Agreement, or the payment of any amounts by
COMPANY to MAYO under this Agreement; (b) based on the Patent Rights; or (c) related to use, sale or importation of the Licensed Product. The parties acknowledge that MAYO is a U.S. not-for profit
entity and is not expected to have any tax liability, and shall provide to COMPANY a tax certificate reflecting its not for profit status. If COMPANY is nevertheless required by law to withhold on remittance of the royalty payments, COMPANY shall
PAY to MAYO amounts which shall result in the net 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 9
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 
amount being received by MAYO being equal to the amount which would have been received by MAYO had no such deduction or withholding been made. In any such case, COMPANY will provide MAYO with
reasonable assistance, at MAYO’s expense, in obtaining, any tax reduction (including avoidance of double taxation), tax refund or tax exemption available to MAYO by treaty or otherwise. 

3.09 U.S. CURRENCY. All payments to MAYO under this Agreement will be made by draft drawn on a U.S. bank, and payable in U.S. dollars. In the event
that conversion from foreign currency is required in calculating a payment under this Agreement, the exchange rate used shall be the Interbank rate quoted by US Bank at the end of the last business day of the quarter in which the payment accrued.

 3.10 OVERDUE PAYMENTS. If overdue, the payments due under this Agreement shall bear interest until paid at a per annum rate of [***] in effect at
US Bank on the due date. MAYO shall be entitled to recover, in addition to all other remedies, reasonable attorneys’ fees and costs related to the administration or enforcement of this Agreement, including collection of payments, following
COMPANY’s such failure to pay. The acceptance of any payment, including such interest, shall not foreclose MAYO from exercising any other right or seeking any other remedy that it may have as a consequence of the failure of COMPANY to make any
payment when due. 
 Article 4.00 - Accounting and Reports 

4.01 REPORTS AND PAYMENT. Commencing with the First Commercial Sale of a Licensed Product, COMPANY will deliver to MAYO on or before the following
dates: 1 August, a written report setting forth a full accounting showing how any amounts due to MAYO for the preceding calendar year have been calculated as provided in this Agreement, including an accounting of total Net Sales with a
reporting of any applicable foreign exchange rates, deductions, allowances, and charges and any payments due from Sublicensees. Each report will include product names, part numbers and quantity sold for each country in which the Licensed
Product was sold. Furthermore, the report will include detailed information about Licensed Products sold to MAYO or MAYO Affiliates at cost, pursuant to Section 3.04 (Earned Royalties) or 3.07 ([***]). If no Licensed Product transfers have
occurred and no other amounts are due to MAYO, COMPANY will submit a report so stating. Each such report will be accompanied by the payment of all amounts due for such calendar year. 

4.02 ACCOUNTING. COMPANY will, throughout the Term, keep complete, continuous, true and accurate books of accounts and records sufficient to support
and verify the calculation of Net Sales, all royalties and any other amount believed due and payable to MAYO under this Agreement. Such books and records will be open once per year during COMPANY’s ordinary business hours for inspection by a
nationally recognized accounting firm selected by MAYO for audit and verification of royalty statements under this Agreement. The MAYO representative will be required to enter into a written confidentiality agreement with the COMPANY and will be a
firm reasonably acceptable to COMPANY. MAYO will provide to the COMPANY a copy of any report by the accounting firm that concludes that any underpayment occurred, along with supporting documentation. In the event such audit reveals an underpayment
by COMPANY in 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 10
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 
any year, and COMPANY does not reasonably dispute such conclusion, COMPANY will within [***] pay the amount underpaid royalty due in excess of the royalty actually paid. In the event the audit
reveals an underpayment by COMPANY of more than [***] of the amount due to MAYO in any year, COMPANY will pay interest on the royalty due in excess of the royalty actually paid at the highest rate then permitted by law and COMPANY will pay all of
MAYO’s costs in conducting the audit. 
 Article 5.00 - Diligence 

5.01 DEVELOPMENT PLAN. COMPANY will make commercially reasonable efforts to bring Licensed Products to market in the Field in the Territory. COMPANY
has provided MAYO with a development plan that describes how COMPANY intends to bring Licensed Products to market, attached to this Agreement as Schedule B, Development Plan, incorporated herein by reference. The Development Plan is subject
to reasonable revision by Evelo based on data and results generated in development of Licensed Products. Activities conducted by the COMPANY and its Affiliates and Sublicensees shall be treated as efforts by the Company in determining compliance
with this Section 5. 
 5.02 DILIGENCE REPORTS. COMPANY will provide MAYO with annual reports within [***] of each anniversary of the Effective
Date describing in detail: (a) as of that reporting period, all development and marketing activities for the Licensed Product and the names of all Sublicensees, including which of the Sublicensees are Affiliates. MAYO shall have the right to
audit COMPANY’s and Sublicensees’ records relating to development of Licensed Products. The foregoing Diligence Report obligations will terminate upon first commercial sale of a Licensed Product. 

Article 6.00 – Intellectual Property Management 

6.01 CONTROL. MAYO will have the responsibility to prepare, file, prosecute, abandon, or otherwise handle the Patent Rights with prior advice and
comment from COMPANY. COMPANY shall pay all costs and expenses associated with the filing, prosecution and maintenance of the Patent Rights, whether arising before or during the Term; provided, COMPANY may with [***] prior written notice to MAYO
discontinue its financial support for such activities with respect to any patent application or patent within the Patent Rights, and in such case, the COMPANY’s license to the applicable patent or patent application shall terminate. Unless
otherwise agreed by the parties in writing, MAYO shall have sole control over the protection, defense, enforcement, maintenance, abandonment and other handling of the Know-How and Licensed Materials. Provided
that MAYO considers COMPANY’s comments in good faith, MAYO will have no liability to COMPANY for any act or omission in the preparation, filing, prosecution, maintenance, abandonment, or other handling of the Patent Rights, Know-How and Licensed Materials. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 11
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 6.02 ENFORCEMENT. If COMPANY becomes aware of a third party infringement of any unexpired claim within
the Patent Rights, COMPANY will promptly provide MAYO with written notice and if possible provide MAYO the available information supporting that infringement has occurred. The parties shall discuss in good faith whether the article infringes one
more claims of the Patent Rights. COMPANY will have the first right, but not the obligation to assert the Patent Rights against any such infringement, using counsel of its choice, and at its expense. MAYO shall not be required to join such action
unless it has agreed to do so in writing prior to the commencement thereof, or unless a necessary party, but in all cases MAYO shall reasonably cooperate in any such proceeding if requested to do so by COMPANY and at COMPANY’S expense. In the
event of any recovery in such an action, COMPANY may first recover its costs and expenses, and any remainder shall be treated as Net Sales. In the event that COMPANY does not choose to assert the Patent Rights against any such infringement, COMPANY
will provide written notice to MAYO advising of COMPANY’s decision and, at MAYO’s request, the parties shall discuss COMPANY’s strategy to protect revenues from the sale of Licensed Products. 

6.03 PATENT TERM EXTENSION. MAYO shall consult with COMPANY in selecting the patent covering each Licensed Product for patent term extension for or
supplementary protection certificate under in accordance with the applicable laws of any country; provided, COMPANY shall have the first right to decide as to whether a patent term extension shall be sought for any patent within the Patent Rights
with regard to a particular Licensed Product. If COMPANY declines to pursue and pay a patent term extension and MAYO decides to pay for the patent term extension, COMPANY’S license to the Patent Rights shall terminate. Each Party agrees to
execute any documents and to take any additional actions as the other Party may reasonably request in connection therewith. For the avoidance of doubt, the Company shall have the right, at its discretion, whether to elect to seek patent term
restoration for any Licensed Patent in any country. 
 6.04 PATENT MARKING. To the extent commercially feasible, COMPANY will mark all Licensed
Products that are manufactured or sold under this Agreement with the number of each issued patent within the Patent Rights that cover such Licensed Product(s). Any such marking will be in conformance with the patent laws and other laws of the
country of manufacture or sale. 
 6.05 DEFENSE. COMPANY will have the first right, but not the obligation, to take any measures deemed appropriate
by COMPANY, regarding (a) challenges to the Patent Rights (including interferences, inter partes review, post grant review, cover business method, ex parte examination, or derivation proceedings in the U.S. Patent and Trademark Office and
oppositions in foreign jurisdictions) and (b) defense of the Patent Rights (including declaratory judgment actions) at COMPANY’s expense. 

6.06 THIRD PARTY LITIGATION. In the event a third party institutes a suit against COMPANY for patent infringement involving a Licensed Product, COMPANY
will promptly inform MAYO and keep MAYO regularly informed of the proceedings. COMPANY agrees to indemnify, defend and hold harmless MAYO for any claims, demands or law suits related thereto.      

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 12
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 Article 7.00 – Use of Name 

7.01 USE OF NAME AND LOGO. Except as permitted by Section 8.03, COMPANY will not use for publicity, promotion or otherwise, any logo, name, trade
name, service mark or trademark of MAYO or its Affiliates, including, but not limited to, the terms “MAYO®,” “MAYO
Clinic®” and the triple shield MAYO logo, or any simulation, abbreviation or adaptation of the same, or the name of any MAYO employee or agent, without MAYO’s prior, written, express
consent. MAYO may withhold such consent in MAYO’s absolute discretion. With regard to the use of MAYO’s name, all requests for approval pursuant to this Section must be submitted to the [***], at the following e-mail address: [***] at least five (5) business days prior to the date on which a response is needed. 

Article 8.00 - Confidentiality 
 8.01
TREATMENT OF CONFIDENTIAL INFORMATION. Except as provided for in Section 8.02 (Right to Disclose), neither Party will disclose, use or otherwise make available the other’s Confidential Information during the Term and for three
(3) years thereafter and will use at least the same degree of care it employs to protect its own confidential information. 
 8.02 RIGHT TO
DISCLOSE. 
  

	 	(a)	To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, COMPANY may disclose Confidential Information of MAYO to its Sublicensees, consultants, and
outside contractors and potential investors and business partners on the condition that each such entity or person agrees to obligations of confidentiality and non-use at least as stringent as those herein.

  

	 	(a)	To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, MAYO may disclose Confidential Information of COMPANY to its consultants and outside
contractors on the condition that each such entity agrees to obligations of confidentiality and non-use at least as stringent as those herein. 

 

	 	(b)	If a Party is required by law, regulation or court order to disclose any of the Confidential Information, it will have the right to do so, provided it: (i) promptly notifies the disclosing Party; and
(ii) reasonably assists the disclosing Party to obtain a protective order or other remedy of disclosing Party’s election and at disclosing Party’s expense, and only disclose the minimum amount necessary to satisfy such obligation.

 8.03 CONFIDENTIALITY OF AGREEMENTS. Except as otherwise required by law, the specific terms and conditions of this Agreement shall
be Confidential Information but the existence of this Agreement will not be Confidential Information and the Parties may state that COMPANY is licensed under the Patent Rights. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 13
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 Article 9.00 – Warranties, Representations, Disclaimers and Indemnification 

9.01 REPRESENTATIONS AND WARRANTIES OF COMPANY. COMPANY warrants and represents to MAYO that: 

 

	 	(a)	it is engaged in the development, production, quality control, service, manufacture, marketing and sales of products similar to the subject matter of the Patent Rights, and that it will commit itself to a thorough,
vigorous and diligent program of developing and marketing the Licensed Products; 

  

	 	(b)	it has independently evaluated the Patent Rights, Know-How and Licensed Materials and Confidential Information, if any, their applicability or utility in COMPANY’s
activities, is entering into this Agreement on the basis of its own evaluation and not in reliance of any representation by MAYO, and assumes all risk and liability in connection with such determination; 

 

	 	(c)	it now maintains and will continue to maintain throughout the Term and beyond insurance coverage as set forth in Section 9.03 (Indemnification and Insurance) and that such insurance coverage sufficiently covers the
MAYO Indemnitees; 

  

	 	(d)	the execution and delivery of this Agreement has been duly authorized and no further approval, corporate or otherwise, is required in order to execute this binding Agreement; 

 

	 	(e)	it shall comply and require its Sublicensees to comply with all applicable international, national and state laws, ordinances and regulations in its performance under this Agreement; and 

 

	 	(f)	its rights and obligations under this Agreement do not conflict with any contractual obligation or court or administrative order by which it is bound. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 14
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 9.02 Representations, Warranties and Covenants of MAYO. MAYO represents
and warrants that: 
  

	 	(a)	It is a not for profit entity, validly existing and in good standing under the laws of Minnesota; 

  

	 	(b)	to the best of Mayo Clinic Ventures knowledge as of the Effective Date, except for the rights retained by the US government, MAYO is the sole and exclusive owner of the Patent Rights, Licensed Materials and Know How;

  

	 	(c)	the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of MAYO, and no further approval, corporate or otherwise is required to enter this
binding Agreement; and 

  

	 	(d)	to the best of Mayo Clinic Ventures knowledge as of the Effective Date, it has not granted any right, license or interest in or to the Patent Rights or Licensed Materials, or any portion thereof, inconsistent with the
licenses granted to the Company in this Agreement. 

 9.03 DISCLAIMERS. 

(a) EXCEPT AS EXPRESSLY PROVIDED IN SECTION 9.02, MAYO HAS NOT MADE AND DOES NOT MAKE ANY PROMISES, COVENANTS, GUARANTEES, REPRESENTATIONS OR
WARRANTIES OF ANY NATURE, DIRECTLY OR INDIRECTLY, EXPRESS, STATUTORY OR IMPLIED, INCLUDING WITHOUT LIMITATION, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, SUITABILITY, DURABILITY, CONDITION, QUALITY OR ANY OTHER CHARACTERISTIC OF THE PATENT
RIGHTS, KNOW-HOW, LICENSED MATERIALS OR CONFIDENTIAL INFORMATION. 
 (b) EXCEPT AS EXPRESSLY PROVIDED
IN SECTION 9.02, THE PATENT RIGHTS, KNOW-HOW, LICENSED MATERIALS AND CONFIDENTIAL INFORMATION ARE PROVIDED “AS IS,” “WITH ALL FAULTS” AND “WITH ALL DEFECTS,” AND COMPANY EXPRESSLY
WAIVES ALL RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST MAYO FOR MISREPRESENTATION OR FOR BREACH OF PROMISE, GUARANTEE, REPRESENTATION OR WARRANTY OF ANY KIND RELATING TO THE PATENT RIGHTS, KNOW-HOW, LICENSED
MATERIALS OR CONFIDENTIAL INFORMATION. MAYO EXPRESSLY DISCLAIMS ANY IMPLIED WARRANTIES ARISING FROM ANY COURSE OF DEALING, USAGE OR TRADE PRACTICE, WITH RESPECT TO: THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS, KNOW-HOW, LICENSED MATERIALS AND CONFIDENTIAL INFORMATION; THAT ANY PATENT WILL ISSUE BASED UPON ANY PENDING PATENT APPLICATION; OR THAT THE USE, SALE, OFFER FOR SALE OR IMPORTATION OF THE LICENSED PRODUCT, PATENT
RIGHTS, KNOW-HOW OR LICENSED MATERIALS WILL NOT INFRINGE OTHER INTELLECTUAL PROPERTY RIGHTS. NOTHING IN THIS AGREEMENT WILL BE CONSTRUED AS AN OBLIGATION FOR MAYO TO BRING, PROSECUTE OR DEFEND ACTIONS
REGARDING THE PATENT RIGHTS, KNOW-HOW, LICENSED MATERIALS AND CONFIDENTIAL INFORMATION. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 15
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 (c) COMPANY AGREES THAT MAYO AND ITS AFFILIATES WILL NOT BE LIABLE FOR ANY LOSS OR DAMAGE
CAUSED BY OR ARISING OUT OF ANY RIGHTS GRANTED OR PERFORMANCE MADE UNDER THIS AGREEMENT, WHETHER TO OR BY COMPANY, SUBLICENSEE OR A THIRD PARTY. IN NO EVENT WILL MAYO’S LIABILITY OF ANY KIND INCLUDE ANY SPECIAL, INDIRECT, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE LOSSES OR DAMAGES, EVEN IF MAYO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR EXCEED THE TOTAL AMOUNT OF ROYALTIES THAT HAVE ACTUALLY BEEN PAID TO MAYO BY COMPANY AS OF THE DATE OF FILING AN ACTION AGAINST MAYO
THAT RESULTS IN THE SETTLEMENT OR AWARD OF DAMAGES TO COMPANY. 
 9.04 INDEMNIFICATION AND INSURANCE. 

(a) COMPANY will defend, indemnify and hold harmless MAYO, MAYO’s Affiliates and their respective trustees, officers, agents, independent
contractors and employees (“MAYO Indemnitees”) from any and all claims, actions, demands, judgments, losses, costs, expenses, damages and liabilities (including attorneys’ fees, court costs and other expenses of litigation),
regardless of the legal theory asserted, arising out of or connected with: (i) the practice or exercise of any rights granted hereunder by or on behalf of COMPANY or any Sublicensee; (ii) research, development, design, manufacture,
distribution, use, sale, importation, exportation or other disposition of Licensed Products; and (iii) any act or omission of COMPANY or any Sublicensee hereunder, including the negligence or willful misconduct thereof or breach of
Section 11.05 (Anti-Corruption Compliance). MAYO and MAYO’s Affiliates shall have no obligation to indemnify COMPANY hereunder.  

(b) The Parties agree that this indemnity should be construed and applied in favor of maximum indemnification of MAYO Indemnitees. 

(c) COMPANY will continuously carry occurrence-based liability insurance, including products liability and contractual liability, in an amount
and for a time period sufficient to cover the liability assumed by COMPANY hereunder during the Term and after, such amount being [***]. In addition, such policy will name MAYO and its Affiliates as additional-named insureds. The minimum limits of
any insurance coverage required herein shall not limit COMPANY’s liability. 
 (d) COMPANY expressly waives any right of subrogation
that it may have against MAYO Indemnitees resulting from any claim, demand, liability, judgment, settlement, costs, fees (including attorneys’ fees) and expenses for which COMPANY is obligated to indemnify, defend and hold MAYO Indemnitees
harmless under this Agreement. 
 9.05 PROHIBITION AGAINST INCONSISTENT STATEMENTS. COMPANY shall not make any statements, representations or
warranties, or accept any liabilities or responsibilities whatsoever that are inconsistent with any disclaimer or limitation included in this section or any other provision of this Agreement. COMPANY shall not settle any matter that will incur
liability for MAYO or require MAYO to make any admission of liability without MAYO’s prior written consent. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 16
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 Article 10.00 - Term and Termination 

10.01 TERM. This Agreement will expire at the end of the Term. 

10.02 TERMINATION FOR BREACH. If COMPANY commits a material breach of this Agreement, including without limitation, the failure to make any required
royalty or fee payments hereunder, MAYO will notify COMPANY in writing of such breach and COMPANY will have [***] after such notice to cure such breach to MAYO’s reasonable satisfaction. If COMPANY fails to timely cure such breach, MAYO may
terminate this Agreement in whole by sending COMPANY written notice of termination. 
 10.03 TERMINATION FOR SUIT. MAYO may immediately terminate
this Agreement if COMPANY or any Sublicensee directly or indirectly brings any action or proceeding against MAYO or its Affiliates, except for an uncured material breach of this Agreement by MAYO. 

10.04 INSOLVENCY OF COMPANY. This Agreement terminates immediately without an obligation of notice of termination to COMPANY in the event COMPANY
ceases conducting business in the normal course, becomes insolvent or bankrupt, makes a general assignment for the benefit of creditors, admits in writing its inability to pay its debts as they are due, permits the appointment of a receiver for its
business or assets or avails itself of or becomes subject to any proceeding under any statute of any governing authority relating to insolvency or the protection of rights of creditors. 

10.05 RETURN/DESTRUCTION OF LICENSED MATERIALS. In the event of a termination pursuant to this Article 10 (Term and Termination) and at
MAYO’s sole discretion, COMPANY shall either return the Licensed Materials to MAYO or destroy it. If COMPANY is instructed by MAYO to destroy the Licensed Materials, COMPANY shall provide to MAYO destruction certification within [***] of
destroying. 
 10.06 SURVIVAL. The termination or expiration of this Agreement does not relieve either Party of its rights and obligations that have
previously accrued. After the Term, all rights granted immediately revert to MAYO. All Confidential Information of a Party shall be returned or destruction certified, at the disclosing party’s election. Rights and obligations that by their
nature prescribe continuing rights and obligations shall survive the termination or expiration of this Agreement including Sections 4.02 (Accounting), 9.03 (Indemnification and Insurance), 10.05 (Return/Destruction of Licensed Material), 10.06
(Survival) and Articles 7 (Use of Name), 8 (Confidentiality) and 11 (General Provisions). COMPANY, on behalf of itself and its Sublicensees, shall provide an accounting for and pay, within [***] of termination or expiration, all amounts due
hereunder. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 17
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 Article 11.00 - General Provisions 

11.01 AMENDMENTS. This Agreement may not be amended or modified except by a writing signed by both Parties and identified as an amendment to
this Agreement. 
 11.02 CONSTRUCTION. Each Party acknowledges that it was provided an opportunity to seek advice of counsel and as such this
Agreement shall not be construed for or against either Party. 
 11.03 ENTIRE AGREEMENT. This Agreement constitutes the final, complete and exclusive
agreement between the Parties with respect to its subject matter and supersedes all past and contemporaneous agreements, promises, and understandings, whether oral or written, between the Parties, including without limitation, the Material Transfer
Agreement entered by COMPANY and MAYO effective October 18, 2016. 
 11.04 EXPORT CONTROL. The Parties agree not to use or otherwise export or re-export anything exchanged or transferred between them pursuant to this agreement except as authorized by United States law and the laws of the jurisdiction in which it was obtained. In particular, but without
limitation, items exchanged may not be exported or re-exported (a) into any U.S. embargoed countries or (b) to anyone on the U.S. Treasury Department’s list of Specially Designated Nationals or
the U.S. Department of Commerce Denied Person’s List or Entity List. By entering into this Agreement, each Party represents and warrants that they are not located in any such country or on any such list. Each Party also agrees that they will
not use any item exchanged for any purposes prohibited by United States law, including, without limitation, the development, design, manufacture or production of missiles, or nuclear, chemical or biological weapons. In the event either Party becomes
aware of any suspected violations of this paragraph that Party will promptly inform the other Party of such suspected violations, and cooperate with one another in any subsequent investigation and defense, be they civil or criminal. 

11.05 ANTI-CORRUPTION COMPLIANCE. The Parties, their Affiliates, and any Sublicensee, shall conduct themselves in an ethical, lawful, businesslike and
professional manner in performance of this Agreement and shall comply with all applicable laws, regulations and directives that may apply to them in the United States or elsewhere. Without limiting the foregoing and for avoidance of doubt, COMPANY,
its Affiliates, and any Sublicensee, shall obey the U.S. Foreign Corrupt Practices Act (“FCPA”) (15 USC §§ 78dd-1, et seq.) and any similar applicable anti-bribery provisions, laws or
regulations. Each party shall reasonably assist the other party(ies) to assure such compliance at all times during the term of this Agreement. COMPANY’s, its Affiliates, or any Sublicensee’s failure to adhere to the requirements of this
section shall be grounds for Mayo to terminate this Agreement immediately for cause. 
 11.06 GOVERNING LAW AND JURISDICTION. The terms and
conditions of this Agreement, as well as all disputes arising under or relating to this Agreement, shall be governed by Minnesota law, specifically excluding its
choice-of-law principles, except that the interpretation, validity and enforceability of the Patent Rights will be governed by the patent laws of the country in which
the patent application is pending or issued. This is not an Agreement for the sale of goods and as such Article 2 of the Uniform Commercial Code as enacted in Minnesota does not apply. The exclusive fora for the foregoing are the State or District
Court of Olmsted County, Minnesota, unless such action cannot by law be brought in such forum, in which case the venue required by law shall govern. COMPANY agrees unconditionally that it is personally subject to the jurisdiction of such courts.

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 18
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 11.07 HEADINGS. The headings of articles and sections used in this document are for convenience
of reference only. 
 11.08 INDEPENDENT CONTRACTORS. It is mutually understood and agreed that the relationship between the Parties is that of
independent contractors. Neither Party is the agent, employee, or servant of the other. Except as specifically set forth herein, neither Party shall have nor exercise any control or direction over the methods by which the other Party performs work
or obligations under this Agreement. Further, nothing in this Agreement is intended to create any partnership, joint venture, lease or equity relationship, expressly or by implication, between the Parties. 

11.09 INDUCEMENT OF REFERRALS. It is not the purpose of this Agreement or the intent of the Parties to induce or encourage the referral of patients,
and there is no requirement under this Agreement or under any other Agreement between the Parties that COMPANY or its staff refer patients to MAYO for products or services. No payment made under this Agreement is made in return for the referral of
patients, or is made in return for the purchasing, leasing, or ordering of any products or services. 
 11.10 LIMITATION OF RIGHTS CREATED. This
Agreement is personal to the Parties and shall be binding on and inure to the sole benefit of the Parties and their permitted successors and assigns and shall not be construed as conferring any rights to any third party. Specifically, no interests
are intended to be created for any customer, patient, research subjects, or other persons (or their relatives, heirs, dependents, or personal representatives) by or upon whom the Licensed Products may be used. 

11.11 NO ASSIGNMENT. Neither Party may assign its rights hereunder to any third party without the prior written consent of the other Party;
provided, that a Party may assign this Agreement and/or its rights arising hereunder without the prior written consent of the other Party to (i) any affiliate or other entity that controls, is controlled by or is under common control with such
Party; or (ii) in connection with a merger, acquisition, or other consolidation by COMPANY or sale of all or substantially all assets relating to the relevant rights provided the assignee agrees to be legally bound to all of COMPANY’S
applicable obligations under this Agreement. Any purported assignment in violation of this clause is void. Such written consent, if given, shall not in any manner relieve the assignor from liability for the performance of this Agreement by its
assignee.  
 11.12 NOTICES. All notices and other business communications between the Parties related to this Agreement shall be in writing,
sent by certified mail, addressed as follows: 
  

	 	To MAYO:	Mayo Foundation for Medical Education and Research 

 Mayo Clinic Ventures – BB4 

200 First Street SW 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 19
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 Rochester, Minnesota 55905-0001 

Attn: Ventures Operations 

Phone: [***] 
 Facsimile: [***]

 Email: [***] 
 Fed Tax ID:
[***] 
 To COMPANY: 
 Fed Tax
ID: 46-5594527 
 Legal Contact: 

Evelo Biosciences, Inc. 
 Legal
Department 
 620 Memorial Drive, Suite 200 

Cambridge, Massachusetts 02139 

Facsimile: [***] 
 Email: [***]

 Invoicing Contact: 
 Evelo
Biosciences, Inc. 
 Accounts Payable 

620 Memorial Drive, Suite 200 

Cambridge, Massachusetts 02139 

Facsimile: [***] 
 Email: [***]

 Expense Reimbursement Contact: 

Evelo Biosciences, Inc. 

Finance Department 
 620
Memorial Drive, Suite 200 
 Cambridge, Massachusetts 02139 

Facsimile: [***] 
 Email: [***]

 Notices sent by certified mail shall be deemed delivered on the third day following the date of mailing. Either Party may change its address or facsimile
number by giving written notice in compliance with this section. 
 11.13 REGISTRATION OF LICENSES. COMPANY will register and give required notice
concerning this Agreement, at its expense, in each country in the Territory where an obligation under law exists to so register or give notice. 
 11.14
SEVERABILITY. In the event any provision of this Agreement is held to be invalid or unenforceable, the remainder of this Agreement shall remain in full force and effect as if the invalid or unenforceable provision had never been a part of the
Agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 20
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 11.15 WAIVER. The failure of either Party to complain of any default by the other Party or to enforce
any of such Party’s rights, no matter how long such failure may continue, will not constitute a waiver of the Party’s rights under this Agreement. The waiver by either Party of any breach of any provision of this Agreement shall not be
construed as a waiver of any subsequent breach of the same or any other provision. No part of this Agreement may be waived except by the further written agreement of the Parties. 

This Agreement may be executed in any number of counterparts which, when taken together, will constitute an original, and photocopy,
facsimile, electronic or other copies shall have the same effect for all purposes as an ink-signed original. Each Party hereto consents to be bound by photocopy, facsimile, or electronic signatures of such
Party’s representative hereto. 
  

									
	MAYO FOUNDATION FOR MEDICAL	 		 	EVELO BIOSCIENCES, INC.
	EDUCATION AND RESEARCH 	 		 		 	
					
	By	 	/s/ James A. Rogers, III	 		 	By	 	/s/ Balkrishan Simba Gill
		 	Name: James A. Rogers, III	 		 		 	Name: Balkrishan Simba Gill
		 	Title: Assistant Secretary	 		 		 	Title: Chief Executive Officer
			
	Date: 8/7/17	 		 	Date: 8/7/17

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 21
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 Schedule A - Licensed Patents 

[***] Patent [***], titled [***] 

[***] Patent [***], titled [***] 

[***] Patent [***], titled [***] 

[***] Patent Application No. [***], filed [***], titled [***] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

 

					
	FINAL License Agreement	  		  	 page 
 22
 of 22
	MAYO [***]/ Evelo	  		  	8/07/2017

  

 Schedule B- Development Plan 

Subject to reasonable revision based on data generated in development of Licensed Products. Company will: 

 

	 	1.	Secure board approval of Prevotella histicola as a candidate for clinical development within [***] of effective date 

  

	 	2.	File for IND or CTA within [***] of Effective Date 

  

	 	3.	Begin clinical study in patients (not a healthy volunteer study) within [***] of IND or CTA filing 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.EX-10.15

 Exhibit 10.15 

Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
 EXCLUSIVE LICENSE
AGREEMENT 
 BETWEEN THE UNIVERSITY OF CHICAGO AND EVELO BIOSCIENCES 

FOR AN IMMUNO-ONCOLOGY TECHNOLOGY 
 This
License Agreement (“Agreement”), dated March 10, 2016 (the “Effective Date”), is between The University of Chicago, an Illinois not-for-profit
corporation (“University”), and Evelo Biosciences, Inc., a Delaware corporation, having an address at 620 Memorial Drive, Suite 200 Cambridge, Massachusetts 02139. (“Company”). Each hereunder may be referred to separately as the
“Party”, or together as the “Parties”. 
 WHEREAS, University has certain Licensed Patents and Technical Information arising from the
disclosure entitled, “Treatment of Cancer by Manipulation of Commensal Microflora” regarding the work of Thomas Gajewski, Leticia Corrales, and Ayelet Sivan, funded in part by the U.S. government; 

WHEREAS, Company wishes to obtain an exclusive license under such Licensed Patents and access such Technical Information to diligently develop and
commercialize Licensed Products; and 
 WHEREAS, University is willing to grant such rights in accordance with the terms and conditions of this Agreement to
afford the public access to Licensed Products. 
 NOW, THEREFORE, for good and valuable consideration, the Parties agree as follows: 

 

	1.	Definitions 

 The capitalized terms listed below and used in this Agreement will have the
following meanings: 
  

	 	A.	“Affiliate” means any corporation or other entity that directly or indirectly controls, is controlled by, or is under common control with, a party hereto where “control” means direct or indirect
ownership of, or other beneficial interest in, fifty percent (50%) or more of the voting stock, other voting interest, or income of a corporation or other entity or the ability to direct the affairs of such other entity through contract rights or
otherwise. 

  

	 	B.	“Calendar Quarter” means each of the four, three-month periods ending on March 31st, June 30th,
September 30th, and December 31st. 

  

	 	C.	“Combination Product” means a product that contains one or more Licensed Product(s) and one or more other therapeutically active components sold as a unit at a single price. For clarity, a Combination Product
may contain multiple Licensed Products (e.g., bacterial strains). 

  

					
	7805096	  	Page 1 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	D.	“Commence” or “Commencement” means, with respect to any clinical trial, the first dosing of the first patient in such clinical trial. 

 

	 	E.	“EMA” means the European Medicines Agency or any successor agency thereto. 

  

	 	F.	“FDA” means the United States Food and Drug Administration or any successor agency thereto. 

  

	 	G.	“Field” means all uses. 

  

	 	H.	“First Commercial Sale” means the first sale, lease, provision of service, use, or transfer of a Licensed Product by a Licensed Entity to a third party for consideration. 

 

	 	I.	“First Human Testing” means the Commencement of dosing of a Licensed Product in human patients. 

  

	 	J.	“IND” means an Investigational New Drug application, or similar application or submission filed by Company for approval to conduct human clinical investigations filed with or submitted to a regulatory
authority in conformance with the requirements of such regulatory authority. 

  

	 	K.	“Intent to Treat Population” means, with respect to a clinical trial, the target population of patients (identified by enrollment criteria) as having a condition for which the Licensed Product will be tested
for efficacy as a primary endpoint. 

  

	 	L.	“Licensed Entity” means Company, an Affiliate of Company, or a Sublicensee. 

  

	 	M.	“Licensed Patents” means, (i) the patent applications listed on Schedule A attached hereto, (ii) all divisions, continuations, foreign counterparts of any of the foregoing, (iii) any
claims in continuations-in-part of any of the foregoing that are fully supported under 35 U.S.C. §112, and (iv) any patents which may issue from such patent
applications and any reexamination, reissues, substitutions, extensions of or to or supplementary protection certificates referencing any of the foregoing patents or patent applications. For clarity, “Licensed Patents” shall not include
any claims in continuations-in-part of the foregoing that are not fully supported under 35 U.S.C. §112 by the patents and patent applications listed on Schedule
A. 

  

	 	N.	“Licensed Product” means: (i) any product, device, system, article of manufacture, machine, composition of matter, process, or service (or component thereof); (ii) any method of using any of the
foregoing; or (iii) any process for making any of the foregoing, that, in the case of (i), (ii), or (iii), either (a) is covered by a Valid Claim of the Licensed Patents, or (b) materially incorporates, utilizes, or is made with the
use of Technical Information. 

  

					
	7805096	  	Page 2 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	O.	“Net Sales” means the gross amount invoiced by Company and Licensed Entities for sales, leases or other transfers, provision of service, or use of Licensed Products after deduction of all the following
determined in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) or International Financial Reporting Standards (“IFRS”), as designated and used by Company and Licensed Entities, as
applicable, in preparing its consolidated financial statements from time to time, in each case, solely to the extent documented to University as directly attributable to one or more Licensed Products and included in the invoiced amount for such
Licensed Products: 

  

	 	i.	customary trade, quantity, or cash discounts and rebates (including chargebacks and allowances), actually allowed and taken (e.g., rebates and similar payments made with respect to sales paid for by any governmental or
regulatory authority such as, by way of illustration and not in limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state program or equivalent foreign governmental program); 

 

	 	ii.	amounts repaid or credited to customers on account of rejections, returns or recall of goods, rebates or bona fide price reductions; 

 

	 	iii.	customs, and excise duties, sales taxes and other governmental customs charges paid by or on behalf of a Licensed Entity; 

  

	 	iv.	reasonable charges for delivery or transportation and insurance relating to such delivery or transportation provided by and paid by a Licensed Entity to a third party (excluding amounts reimbursed); and

  

	 	v.	any invoiced amounts that are not collected by Company and its Licensed Entities, including bad debts relating to such Licensed Products, such deductions only to be taken after Company’s and Licensed Entities’
write-off of such uncollected amounts or bad debts. 

 Net Sales also includes the fair
market value of any non-cash consideration received by a Licensed Entity for the sales, leases, or other transfers or use of Licensed Products, or any right, title, or interest in Licensed Products. Fair
market value will be calculated as of the time of transfer of such non-cash consideration to Licensed Entity. Transfer of a Licensed Product within or between Licensed Entities for sale by the transferee will
not be considered a Net Sale for purposes of calculating Royalties. In such circumstances, the gross sales price and resulting Net Sales price will be based upon the sale of the Licensed Product by the transferee. For Licensed Products consumed by a
Licensed Entity, the price used to calculate Net Sales will be equal to the list price of the same or a substantially similar Licensed Product. 

  

					
	7805096	  	Page 3 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 In the event that one or more Licensed Products are sold in a Combination Product, Net Sales
from the sale of such Combination Product for each applicable Calendar Quarter will be determined as calculated by multiplying the Net Sales (as determined without reference to this paragraph) of such Combination Product by the fraction A/(A+B),
where A is the average gross selling price in the applicable country of the Licensed Product(s) without any other active components and B is the average gross selling price in the applicable country of any product containing the other
therapeutically active component(s) included in such Combination Product when sold separately in finished form, each during the applicable Calendar Quarter or, if sales of all such products did not occur during such Calendar Quarter, the most recent
Calendar Quarter in which sales of all such products occurred. In the event that the average gross selling price(s) cannot be determined for (i) the Licensed Products without other therapeutically active components or (ii) the product
containing the other therapeutically active components included in the Combination Product, the average gross selling price(s) in the above described equation will be replaced with an estimate of the fair market value of the product(s) for which no
such sales exist, which estimate shall be agreed in good faith by the Parties in writing. For Clarity, Net Sales of a Combination Product in which Licensed Products are the only therapeutically active components will be subject to Net Sales as
determined without reference to this Paragraph. 
  

	 	P.	“Non-Commercial Research Purposes” means use of the Licensed Patents or Technical Information for academic research or other not-for-profit scholarly purposes which are undertaken at a non-profit or government institution, and publishing in connection therewith. 

 

	 	Q.	“Phase II Clinical Trial” means a human clinical trial, in any country, that would satisfy the requirements of 21 C.F.R.3 l2.2l(b). 

 

	 	R.	“Phase III Clinical Trial” means a human clinical trial, in any country, that would satisfy the requirements of 2l C.F.R.312.21 (c). 

 

	 	S.	“Regulatory Approval” shall mean, with respect to a Licensed Product in a particular jurisdiction, all approvals, licenses, registrations or authorizations necessary for the marketing and sales of such
Licensed Product in the Field within such jurisdiction, including approval of a BLA, and approval of labeling and satisfaction of all applicable regulatory and notification requirements in such jurisdiction. For clarity, Regulatory Approval does not
require pricing approval, no matter the applicable law. 

  

	 	T.	“Royalty(ies)” means all amounts payable under Section 3.B of this Agreement. 

  

	 	U.	 “Sublicense” means any agreement entered into by Company or an Affiliate or a Sublicensee with any
third party pursuant to which Company or any Affiliate or Sublicensee receives financial consideration in exchange for: (i) any license to the Licensed Patents or Technical Information is granted, including any rights to make, offer for sale,
use, sell, or import Licensed Products); or (ii) a covenant by Company or an Affiliate or a Sublicensee not to sue a third party for the practice or use of any part of the 

  

					
	7805096	  	Page 4 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	
Licensed Patents or Technical Information; or, (iii) a commitment by third party not to practice or use any part of the Licensed Patents or Technical Information in return for not selling a
generic product based on a Licensed Product. Sublicense shall not include any agreement which Company or its Affiliates enters with a third party to: (a) have Licensed Products made, packaged and labeled by third party contractor(s) and
delivered to Company and its Affiliates or Sublicensees for sale, or (b) distribute Licensed Products. 

  

	 	V.	“Sublicense Revenue” shall mean payments received by Company or its Affiliates from a Sublicensee, including upfront fees, option fees (except to the extent such amounts are used for costs incurred in the
research and/or development of Licensed Products), milestone payments, license maintenance fees, and other payments received by Company or its Affiliates from such third party in consideration for the grant of a Sublicense; provided Sublicense
Revenue shall not include: (a) royalties and profit sharing payments (the Net Sales on which such royalties and profit sharing payments are based shall be subject to royalties under Section 3.B below); (b) amounts received as payment for
equity or debt securities of Company or its Affiliates; (c) option fees, solely to the extent such funds are expended for research and development of Licensed Products; (d) any amounts paid to Company or its Affiliates for reasonable
reimbursement of research and/or product development of Licensed Products, or patent prosecution, defense, enforcement and maintenance expenses for Licensed Patents; and/or (e) payments received for reasonable
pre-clinical or clinical research, development, regulatory activities, manufacturing or commercialization activities for Licensed Products undertaken by or on behalf of Company or its Affiliates (including,
without limitation, fully loaded research and development expenses and related full-time equivalent costs). If intellectual property or products other than the Licensed Patents, Technical Information or Licensed Products are licensed concurrently to
such third party, then Sublicense Revenue shall include only those amounts attributable to the sublicense of the Licensed Patents, Technical Information or Licensed Products, as the case may be, which shall be determined by Company or its Affiliates
in good faith. In any such case, Company shall notify University of its proposed allocation, and the parties shall discuss such matter in good faith. If the Parties are unable to agree on the allocation of Sublicensee Revenue attributable to the
Licensed Patents and Technical Information, either Party may request that such matter be resolved by arbitration by the American Arbitration Association (AAA) in accordance with its procedures under its Commercial Arbitration Rules. The award of the
arbitrator(s) will be binding, and judgment upon the award may be entered in any court having jurisdiction thereof. All ADR proceedings will be conducted in the English language. Each Party will have the right to be represented by counsel in all
aspects of any ADR proceeding. The Parties shall equally share the costs of any such determination. 

  

	 	W.	“Sublicensee” means any person, company, or other entity to which any of the rights granted to Company hereunder are granted under a Sublicense. 

  

					
	7805096	  	Page 5 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	X.	“Technical Information” means, to the extent owned and/or controlled by University, any data (i) specifically listed in Schedule B that is delivered to Company (electronic or hard copy) or
(ii) that is delivered to Company by the inventors during the term of this Agreement and is not the subject of any other agreements with Company. 

  

	 	Y.	“Territory” means worldwide. 

  

	 	Z.	“University Personnel” means each of the inventors named on the Licensed Patents and the staff of UChicagoTech. 

  

	 	AA.	“Valid Claim” means a claim of (a) a pending patent application within the Licensed Rights that has not been pending for more than eight (8) years from the date of its earliest filing priority, or
(b) an issued claim of any unexpired Licensed Patent or a claim of any pending Licensed Patent that has not been held unenforceable, unpatentable, or invalid by a decision of a court or governmental body of competent jurisdiction in a ruling
that is unappealable or unappealed within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. Any
claim that has been pending for more than eight (8) years from the date of its earliest filing priority that later issues shall be a Valid Claim upon its issuance. 

 

	2.	Grant 

  

	 	A.	Grant. Subject to the terms and conditions of this Agreement, University hereby grants to Company and its Affiliates and Company on behalf of itself and its Affiliates accepts: 

 

	 	i.	an exclusive, royalty-bearing license under the Licensed Patents in the Field and Territory to make, have made, use, import, have sold, offer to sell and sell Licensed Products within the Field and within the Territory;
and 

  

	 	ii.	a non-exclusive, royalty-bearing license to use the Technical Information in the Field and Territory to discover, develop, make, have made, use, import, have sold, offer to sell
and sell Licensed Products within the Field and within the Territory. 

  

	 	B.	Technical Information. 

  

	 	i.	Technical Information is provided by University to Company solely for the use permitted in Section 2.A.ii., and nothing herein will be construed as constituting a sale thereof. Unless otherwise specified in writing
by University, Licensed Entities will maintain Technical Information as University’s confidential information during and after the term of this Agreement unless such information is: (a) already known to Licensed Entity at the time of
disclosure as evidenced by the Licensed Entity’s written records; (b) in the public domain other than through acts or omissions of the Licensed Entity, or anyone that accessed the confidential information from the Licensed Entity;
(c) lawfully disclosed to the Licensed Entity by a third party without restriction; or (d) independently developed by the Licensed Entity without knowledge of or access to the confidential information as evidenced by the Licensed
Entity’s written records. 

  

					
	7805096	  	Page 6 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	ii.	Delivery. Within [***] of the Effective Date, University shall deliver (and shall cause its personnel to deliver) to Company, all data, reports, analyses and other information within the Technical Information
that exists and is reasonably available and transferable in a tangible form as of the Effective Date. If at any time during the Term, documents, data or information that exists and is reasonably available and transferable in a tangible form and are
within the Technical Information that were not previously delivered to Company, University shall [***]. 

  

	 	C.	Ongoing Obligations of Former Affiliates. While an entity is entitled to the benefits of an Affiliate under this Agreement for only the period of time the entity qualifies as an Affiliate under the definition (in
accordance with Section 7.C), all obligations under this Agreement that accrued to such entity while an Affiliate will survive until fulfilled even though the entity no longer qualifies as an Affiliate. For clarity, and without limitation, any
entity that is or was an Affiliate of Company may become a Sublicensee. 

  

	 	D.	Sublicense. Subject to the terms and conditions of this Agreement and Company’s and Sublicensee’s compliance therewith, Company and its Affiliates and Sublicensees will have the right to grant
Sublicenses through multiple tiers. Each Sublicense must be granted pursuant to a valid and binding written agreement that expressly states that such Sublicense is subject to, and the applicable Sublicensee must comply with, all the terms and
conditions of this Agreement applicable to the Company. Company will ensure that all Licensed Entities will comply with all the terms and conditions of this Agreement applicable to the Company. Company will have the same responsibility for the
activities of any Licensed Entity as if the activities were directly those of Company. In the event of any inconsistency between the Sublicense and this Agreement, this Agreement will control. Any Sublicense that does not comply with the terms and
conditions of this Agreement is null and void ab initio. Company will provide University with a copy of each Sublicense and any amendments thereof; provided such Sublicense may be redacted to delete any terms not material to compliance
with this Agreement. 

  

	 	E.	Reservation of Rights. The License granted pursuant to the Agreement shall be subject, if applicable, to the rights of the United States government reserved under Public Laws
96-517, 97- 256 and 98-620, codified at 35 U.S.C. 200-212 and UChicago and
University’s Affiliates’s rights to use any inventions claimed in the Licensed Patents for Non-Commercial Research Purposes at its own discretion without any payment to Company for such use.
University reserves the worldwide right to practice or have practiced, and to grant to third parties the right to practice or have practiced Technical Information for any Non-Commercial Research Purposes.

  

					
	7805096	  	Page 7 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 Until the first Regulatory Approval of a Licensed Product in any country, Non-Commercial Research Purposes excludes use in humans except as follows: 
 (a) [***]; and/or 

(b) [***]. 
 (c) [***]. 

(d) For the purposes of clarification, the exclusions described in Sections 2.E.(a), (b) and (c) shall no longer be in effect after the
first Regulatory Approval of a Licensed Product in any country. 
  

	 	F.	U.S. Government Rights. Company understands that this Agreement is subject to any rights of or obligations to the U.S. Government, including under 35 U.S.C. § 200 et seq., 37 C.F.R.
§ 401 et seq. (“Bayh-Dole Act”), or any other applicable law or regulation, including but not limited to the grant to the U.S. Government of a nonexclusive, nontransferable, irrevocable,
paid-up license to practice or have practiced any Subject Invention (as defined in the Bayh-Dole Act) for or on behalf of the U.S. Government throughout the world. Company agrees to comply and permit
University to comply with the Bayh-Dole Act, including to provide the reporting required and to substantially manufacture Subject Inventions and products produced through the use of Subject Inventions in the United States to the extent required
under 35 U.S.C. § 204, unless waived. Company represents to University that as of the Effective Date, Company is a “small business firm” as defined in 15 U.S.C. §632. Company shall promptly notify University if it ceases to be
“small business firm”. 

  

	 	G.	No Other Rights. No rights in and to the Licensed Patents and Technical Information other than those provided in this Section 2, express or implied, are conveyed by University. No rights to any patents
except those included in the Licensed Patents are conveyed by University. Nothing contained in this Agreement or a party’s performance hereunder will be construed as conferring, by implication, estoppel or otherwise, upon any Licensed Entity,
any party in privity with any Licensed Entity, or any customer of any of the foregoing, any right, title or interest under any intellectual or tangible property right at any time, except for those rights expressly granted in Section 2.A. No
rights are granted in this Agreement to any intellectual property owned by Company. 

  

	 	H.	Responsibility for Licensed Entities. Any act or omission taken or made by a Licensed Entity will be deemed an act or omission by Company under this Agreement. Any act, error, or omission of a Licensed Entity
that would be a breach of this Agreement if done by Company will be deemed to be a breach of this Agreement by Company. In the event that Company becomes aware that any Licensed Entity has made any act, error, or omission that would be a breach of
this Agreement if done by Company, Company will promptly notify University thereof. In the event that University believes that any Licensed Entity has breached this Agreement, it shall notify Company with an explanation of its concerns. In any such
case, Company and University shall discuss in good faith such concerns, and means to address any such breach by a Licensed Entity. 

  

					
	7805096	  	Page 8 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	3.	Payments 

  

	 	A.	Upfront Payment. Company will pay University within [***] following the Effective Date, the sum of [***]. 

  

	 	B.	Royalties. Subject to the terms of this Section, Company will pay to University, on a country-by-country and Licensed Product-by-Licensed Product basis, Royalties on annual Net Sales of Licensed Products by Company and Licensed Entities as follows: 

 

	 	i.	Valid Claims Royalty. In country (ies) in which a Licensed Product is covered by a Valid Claim, Company will pay to University: 

 

	 	(a)	[***] for the portion of such annual Net Sales that are less than [***]; 

  

	 	(b)	[***] for the portion of such annual Net Sales that are [***]; and 

  

	 	(c)	[***] for the portion of such annual Net Sales that are greater than [***]. 

Royalties due under this Section 3.B.i will be payable until the later of (i) the expiration of the last-to-expire Valid Claim(s) covering such Licensed Product in such country or (ii) the expiration of any period of regulatory exclusivity for any Licensed Product
obtained as a result of Valid Claims (e.g., orphan drug designation). 
  

	 	ii.	Technical Information Royalty; Unpublished. With regard to annual Net Sales of Licensed Products by Company and Licensed Entities in any country(ies) where there is not a Valid Claim and the relevant Technical
Information has not been published by any person affiliated with the University, Company will pay University a Royalty on a country-by-country and Licensed Product-by-Licensed Product basis, as follows: 

  

	 	(a)	[***] for the portion of such Net Sales on such annual Net Sales that are less than [***]; 

  

	 	(b)	[***] for the portion of such Net Sales on such annual Net Sales that are between [***]; and 

  

	 	(c)	[***] for the portion of such Net Sales on such annual Net Sales that are greater than [***] 

Royalties due under this Section 3.B.ii will be payable on a country-by-country and Licensed Product-by-Licensed Product basis until the earlier of: (i) [***] from the first Commercial Sale
of the applicable Licensed Product in the applicable country, or (ii) until a substantially similar product to the Applicable Licensed Product commences sales in the applicable country. For purposes of this Section 3.ii., a
“substantially similar product” is one that [***]. 

  

					
	7805096	  	Page 9 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	iii.	Technical Information Royalty; Published. With regard to annual Net Sales of Licensed Products by Company and Licensed Entities in any country(ies) where there is not a Valid Claim and the relevant Technical
Information has been published by any University employee, Company will pay University a Royalty on a country-by-country and Licensed Product-by-Licensed Product basis, as follows: 

  

	 	(a)	[***] for the portion of such Net Sales on such annual Net Sales that are less than [***]; 

  

	 	(b)	[***] for the portion of such Net Sales on such annual Net Sales that are between [***]; and 

  

	 	(c)	[***] for the portion of such Net Sales on such annual Net Sales that are greater than [***]. 

Royalties due under this Section 3.B.iii will be payable on a
country-by-country and Licensed Product-by-Licensed Product basis until the earlier of:
(i) fifteen (15) years from the first Commercial Sale of the applicable Licensed Product in the applicable country, or (ii) until a substantially similar product to the Applicable Licensed Product commences sales in the applicable country. For
purposes of this Section 3.iii., a “substantially similar product” is one that [***]. 
  

	 	iv.	Importance of Technical Information. Company has requested, and University has agreed, to grant certain rights to Technical Information. Company requires these rights in order to develop and commercialize the
technology licensed. Because of the importance of Technical Information, Company has agreed to pay certain Royalties to University on Licensed Products, as specified above, even if not covered by a Valid Claim, in order to obtain rights to Technical
Information. Company has agreed to these payments because of the commercial value of Technical Information, separate and distinct from the commercial value of the Licensed Patents. Company acknowledges that the reduced royalty for Licensed Products
that are not covered by a Valid Claim is fair and reasonable in order to compensate University for Company’s continuing license of the Technical Information. 

 

	 	v.	Third Party Licenses. In the event that (a) any patent owned and controlled by any unaffiliated third party (defined as a third party that is not an Affiliate of any Licensed Entity) will be infringed by the
sale of a Licensed Product by the Licensed Entities, (b) the Licensed Product is not sold in combination with other products that are not Licensed Products, and (c) the total royalties due to such unaffiliated third party(ies)
(“Third Party Royalty”) exceeds [***] of Net Sales of such Licensed Product in a Calendar Quarter (“Stacking Threshold”), then the Royalty percentage payable to University may be reduced thereafter, for so long as
Licensed Entities are licensed under the third party patent, by [***]. However, in no event will the Royalty paid to University as a result of the application of this provision be reduced below [***] of the Royalty otherwise due hereunder.

  

					
	7805096	  	Page 10 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	vi.	Single Royalty. Only one Royalty under Section 4.2 shall be paid with respect to each unit of Licensed Product sold, without regard to whether more than one Valid Claim within the Licensed Patents is
applicable to such unit, or multiple bacterial strains that are covered by Valid Claims are included in a particular Licensed Product, or a particular Licensed Product is covered by either one or more Valid Claims and embodies Technical Information.
For clarity, the Royalty due shall be at the highest applicable rate, but shall not be additive of the Royalties due under Section 3.B (i) and (ii). It is understood and agreed that no Royalty shall be due with respect to any use or
transfer of Licensed Products for use in research or development activities conducted for the development of Licensed Products and for which no compensation above manufacturing cost is received by a Licensed Entity. 

 

	 	vii.	Acknowledgement. Except as expressly set forth in this Section 4.2, Licensee shall have no obligation to pay any Royalties to University in consideration for the rights granted in or to the Licensed Patents
or Technical Information. 

  

	 	viii.	Combination Products. The Parties agree that in the event that any Licensed Product is a Combination Product, in no event will the Royalty paid to University with respect to such Licensed Product be reduced by
more [***] of the Royalty otherwise due for such Licensed Product in accordance with Sections 3.B(i), 3.B(ii) and 3.B.(iii). 

  

	 	C.	License Maintenance Fees/Minimum Royalties. Company will pay to University a minimum royalty of [***] per calendar year or part thereof during which this Agreement is in effect. The first of such minimum royalty
payment will be due [***] and subsequent payment will be due on [***] thereafter during the term of this Agreement. Upon termination or expiration of this Agreement, any minimum royalties owed for the period prior to termination will be due within
[***] of such termination or expiration. It is understood that such minimum royalty payments will be fully creditable against Royalties on a calendar year basis, and that sales of Licensed Products requiring the payment of Royalties made during a
prior or subsequent calendar year will have no effect on the annual minimum royalty due University for any other given calendar year. In the event that this Agreement is in effect for only a portion of any calendar year, the minimum royalty payments
set forth in this Section 3.C will be prorated for such portion. 

  

	 	D.	Milestone Payments. Company will notify University within [***] when each of the following events are accomplished regarding each Licensed Product by a Licensed Entity and pay to University the following amounts
(which sums are nonrefundable and noncreditable against Royalties): 

  

					
	7805096	  	Page 11 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	i.	$[***] paid on Commencement of the First Human Testing of the first Licensed Product. For clarity, this milestone would not be due or paid for the commencement of a healthy volunteer study. 

 

	 	ii.	$[***] on acceptance of an IND for the first Licensed Product by the FDA. 

  

	 	iii.	$[***] paid on Commencement of the first Phase III Clinical Trial for the first Licensed Product. 

  

	 	iv.	$[***] paid on Regulatory Approval of each Licensed Product by FDA. 

  

	 	v.	$[***] paid on first Regulatory Approval of each Licensed Product by an applicable regulatory authority in the European Union, such as the (EMA). 

 

	 	vi.	$[***] paid on Regulatory Approval for a 2nd indication of a Licensed Product in the United States (FDA). 

 

	 	vii.	$[***] paid on Regulatory Approval for a 2nd indication of a Licensed Product in the European Union, such as the (EMA). 

Milestones Payments (i)-(iii) shall be paid of maximum of once, regardless of the number of Licensed Products that achieve the applicable
milestone event. Milestones Payments (iv)-(vii) shall be paid of maximum of twice each, regardless of the number of Licensed Products that receive Regulatory Approval. 
  

	 	E.	Payment and Reporting. 

  

	 	i.	Company will pay Royalties owing to University on a quarterly basis, with such amounts due and received by University on or before the [***] following the end of the Calendar Quarter in which such amounts were earned.

  

	 	ii.	Except as otherwise directed, Company will pay all amounts owing to University under this Agreement in U.S. dollars to University at the address provided in Section 9.D or paid via wire transfer, if agreed upon.
Any necessary conversion of currency into United States dollars will be at the applicable rate of exchange of Citibank, N.A. (or its successor), in New York, New York, on the last day of the Calendar Quarter in which such transaction occurred.
University is exempt from paying income taxes under U.S. law. Therefore, Company will make all payments due under this Agreement without deduction for taxes, assessments, or other charges of any kind which may be imposed on University by any
government outside of the United States or any political subdivision of such government with respect to any amounts payable to University pursuant to this Agreement. At Company’s request, University shall cooperate with Company to document
University’s tax exempt status so that any such deductions or charges can be avoided. Company or the applicable Licensed Entity will assume all such taxes, assessments, or other charges that may reduce University’s net royalties, such as
bank transfer fees. 

  

					
	7805096	  	Page 12 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	iii.	Company will submit to University a full accounting showing how any amounts owing to University under Section 3 have been calculated along with each such payment therefore. For Royalties, such accounting will be on
a per country and Licensed Product basis and will be summarized on the form shown in Schedule C of this Agreement. Such accounting will include completing a quarterly Royalty forecast section. In the event no payment is owed to University, within
[***] after the end of each Calendar Quarter, Company will provide to University a statement setting forth that fact. 

  

	 	iv.	Regardless of the circumstances, no payment made to University is refundable and only Royalty payments are creditable toward the minimum royalty as set forth in Section 3.C. 

 

	 	F.	Sublicense Revenue. In addition to payments due pursuant to Sections 3.B and 3.D, Company will pay to University a share of Sublicense Revenue, as follows: 

i. With respect to any Sublicense entered by Company on or before [***], Company will pay to University [***] of any Sublicense Revenue
received with regard to such Sublicense; 
 ii. With respect to any Sublicense entered by Company after [***] but before the filing of an
IND for the first Licensed Product, Company will pay to University [***] of any Sublicense Revenue received with regard to such Sublicense; provided, in such case, the aggregate Sublicensee Revenue payments to University would be a maximum of [***];

 iii. With respect to any Sublicense entered by Company after the filing of an IND for the first Licensed Product, Company will pay to
University [***] of any Sublicense Revenue received with regard to such Sublicense; provided, in such case, the aggregate Sublicensee Revenue payments to University would be a maximum of [***] 

Sublicense Revenue payments shall be made to University within [***] of receipt of such Sublicense Revenue by Company. 

 

	 	G.	Overdue Payments. Any payments by Company that are not received by University on or before the date such payments are due under this Agreement will accrue interest at the lesser of: (i) [***]; and (ii) the
maximum rate allowed by law. Interest will accrue beginning on the first day following the due date for payment and will be compounded monthly. Payment of such interest by Company will not limit, in any way, University’s right to exercise any
other remedies University may have as a consequence of the lateness of any payment. Company will be responsible for all costs of collection incurred by University including attorney’s fees and court costs. 

  

					
	7805096	  	Page 13 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	H.	Good Faith. It is the expectation of the Parties that Company will pay to University the amounts set forth in this Agreement for the commercial exploitation of the Licensed Patents and Technical Information, and
Company will use reasonable efforts to comply with its obligations hereunder. 

  

	4.	Diligence 

  

	 	A.	Development Obligations. Company will use commercially reasonable efforts to diligently develop and bring Licensed Products to market. In particular, Company will use commercially reasonable efforts to meet the
development milestones for advancement of Licensed Products in accordance with Schedule D attached hereto. Activities conducted by the Company and its Affiliates and Licensed Entities shall be treated as efforts by the Company in determining
compliance with this Section 4. 

  

	 	B.	Development Plan. Within [***] following the Effective Date, Company will provide University with a development plan for achievement within [***] of at least [***] development objectives for a Licensed Product.
Such plan will include detailed plans (including proposed expenses for such activities), timetables for achieving milestones and necessary government or regulatory approvals, market research information on competitors and market size, and sales and
marketing plans for the [***] period following the Effective Date, as well as a general plan and estimated timetable for achieving milestones and Company’s strategic development plans for the following three years. Company will revise the
development plan on an annual basis and provide University with such revised plan within [***] of December 31st, concurrent with the progress report due under Section 5.B. Upon request, Company will meet with University in a timely
manner to review any such development plan. Company will use reasonable commercial efforts to perform in substantial compliance with the then-current development plan. 

 

	 	C.	Delay in Achievement of Milestones. If there is a delay in achieving a development objective set forth in a development plan subject to section 4.B., then Company may nonetheless establish that it is using
commercially reasonable efforts and not in breach of this Agreement: 

  

	 	i.	If Company fails to timely accomplish any development objectives due to one or more factors outside of Company’s control, then [***]. It is understood and agreed that factors outside Company’s control shall
include, without limitation, [***]; or 

  

	 	ii.	 If Company fails to timely accomplish any development objectives to factors within Company’s control, then
Company may nonetheless establish that it is using commercially reasonable efforts, as follows: (A) if Company believes it can achieve the development objectives within [***] of the development objective date in the

  

					
	7805096	  	Page 14 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	
applicable Development Plan, then Company will notify the University that the development objectives has not been timely achieved but believes it can achieve the development objectives within
[***] of its notice to University. In such case, Company will have the right to achieve the development objectives within the applicable period, and if the development objective is met within such period, Company will have established that it has
used commercially reasonable diligence efforts; or (B) Company may submit to University evidence that [***]. 

 In the
event that Company has demonstrated diligent efforts as described in this Section 4.C., Company shall not be in breach of this Agreement and University may not terminate the Agreement for failure by Company to exercise commercially reasonable
development efforts.
  

	 	D.	Extension of Timelines. If Company has failed to achieve one or more development objectives, and Company is not able to demonstrate that it has exercised commercially reasonable efforts as described in
Section 4.C. then Company may once (and only once) pay to University a license maintenance fee of [***] to maintain the license. Within [***] of such payment, Company will submit new development targets and associated timelines to University,
and the Parties shall discuss such new development objectives and timelines in good faith. In such case, University’s approval of such new development objectives and timelines shall not be unreasonably withheld, conditioned or delayed. However,
if Company fails to achieve the new development objectives, University and Company will negotiate in good faith for [***] to reach new development targets that are reasonable. If University is unwilling to accept these new development objectives,
University may then terminate this Agreement pursuant to Section7.C.(ii). 

  

	 	E.	Specific Obligations. Notwithstanding the other Sections of this Section 4, if Company has failed to (i) file an IND with respect to at least one Licensed Product within [***] following the Effective
Date, or (ii) Commence a clinical trial intended to enroll at least [***] in an intent to treat clinical trial for at least one Licensed Product within [***] of the Effective Date, then University may then terminate this Agreement pursuant to
Section7.C.(ii). 

  

	 	F.	Promotion and Marketing. Company will use commercially reasonable efforts (and in no event less effort or relative expense than the level of resources and talent as is that Company uses for its other products
with similar market potential and proprietary protection) to promote, advertise, and sell the Licensed Products. 

  

	5.	Records and Review 

  

	 	A.	 Full and Accurate Records. University may from time to time and at any reasonable time, not exceeding once
every [***], through independent auditors reasonably acceptable to Company, as University may designate, inspect and copy the books and records of Company in order to verify the payments due hereunder, the accuracy of any reported

  

					
	7805096	  	Page 15 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	
statement by Company, or of any other obligation under this Agreement. Company and its Affiliates will keep, and will cause Sublicensees to keep, continuous, full and accurate books and records
in sufficient detail so that Company’s compliance with its obligations under this Agreement can be properly determined without undue delay or difficulty. Company will use commercially reasonable efforts to obtain the right for University to
inspect and audit the records of Company’s Licensed Entities on the same terms applicable to Company’s books and records. Company agrees to include usual and customary audit provisions in its Sublicenses, and agrees to share with
University the results of any audit it conducts that are relevant to the Licensed Products. If University makes a reasonable determination that an audit of a Licensed Entity may be appropriate, University will notify Company and the Parties will
discuss in good faith the best course of action. University reserves the right to require Company to audit a Licensed Entity. The books and records of Company and Licensed Entities will be maintained for at least [***] after the activity or Royalty
reporting period(s) to which they relate. Books and records will include but not be limited to: accounting general ledgers; invoice/sales registers; original invoice and shipping documents; federal and state business tax returns;company financial
statements; sales analysis reports; inventory and/or manufacturing records; sublicense and distributor agreements; price lists, product catalogs and other marketing materials, in each case, solely as they relate to Licensed Products. Company will,
and will cause all other Licensed Entities to, comply with this Section 5.A. 

 University shall provide to Company a full
copy of any audit report that concludes that Company has underpaid any amount to University, to allow Company to respond to any such report.    Any audit inspection will be made at the expense of University, unless such
examination discloses a discrepancy of [***] or more in the amount of payments due University in any audit period. In such case Company will be responsible for reimbursing University for the examination fee and expenses charged by the auditor along
with the underpayment. Any underpayment will bear interest as described in Section 3.G. Company will pay past due payments for any error, including any payment deficiency for periods prior to the period under inspection, within [***] of written
notice thereof. University and the auditor will maintain in confidence such inspection and the resulting report. The auditor shall, prior to any audit, enter into a confidentiality agreement with Company and, if the audit involves any Licensed
Entity that is not the Company, with the relevant Licensed Entity, and may from time to time consult University and any of its employees or third party counsel on questions as they relate to this Agreement; provided, the auditor may not disclose to
University or its representatives any financial or proprietary information except as required to conduct the inspection, to report and substantiate the results, as otherwise permitted by this Agreement, or if the information is already publicly
known. 

  

					
	7805096	  	Page 16 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	B.	Progress Reports. Within [***] of each June 30 and December 31 during the term of this Agreement, Company will deliver a written report to University, in substantially the form of Schedule E attached
hereto. The report will describe the progress of Company toward achieving the goals of the development plan and bringing Licensed Products to market (and any proposed revisions to the plan developed during the preceding six months). Company will
promptly notify University in writing upon the First Commercial Sale of each Licensed Product and when Company’s obligation to begin making Royalty payments begins. Upon the First Commercial Sale of each Licensed Product, Company will provide
in writing to University the following information: the date of First Commercial Sale, the generic name, and the tradename of each commercial product. Notwithstanding anything to the contrary in this Section 5.B, if Company has made at least
one Royalty payment to University, Company shall only be required to deliver a written report once annually within [***] after December 31 of each calendar year during the term of this Agreement. 

 

	6.	Patents 

  

	 	A.	Prosecution, Defense and Maintenance. University will control the preparation, filing, prosecution, maintenance and abandonment of the Licensed Patents; provided, Company (or its designee) shall have the first
right (but not the obligation) to control the conduct of any post grant proceedings (including any IPR, oppositions, post-grant proceedings and declaratory judgment actions), solely to the extent such post grant proceedings relate to the Licensed
Patents. The party controlling any such activity (i.e., University or Company, as the case may be) will cooperate, and in the case of Company, will cause other Licensed Entities to cooperate in a timely manner in the applicable activities by
(i) disclosing such information as may be requested by the controlling party, (ii) by promptly executing such documents as the controlling party may reasonably request in connection therewith, and (iii) considering in good faith
comments by the non-controlling party in connection with any such activities. In particular, the controlling party shall provide the non-controlling party with a
reasonable opportunity to review and comment on any communications with any patent office before any such communications are filed. Notwithstanding the foregoing, if a post grant proceeding is filed in connection with another claim against the
University, or if the outcome of the action could be materially detrimental to the University or any of its employees, University will retain control of the proceedings. Company will, and will cause each other Licensed Entity to, bear its own costs
in connection with their cooperation with University under this Section 6.A. Upon request, University will provide, or will have its legal counsel provide, Company copies of material documents received or prepared by University in the filing,
prosecution and maintenance of the Licensed Patents. 

  

	 	B.	Patent Costs. University shall conduct the activities it controls pursuant to section 6.A using patent counsel reasonably acceptable to Company. University shall timely file patent applications and patents with
the Licensed Patents in any countries and jurisdictions selected by Company. Company will pay all necessary and reasonable fees and expenses incurred by University relating to the preparation, filing, prosecution, defense, and maintenance of the
Licensed Patents that University controls (“Patent Costs”). 

  

					
	7805096	  	Page 17 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	i.	Payment for Patent Costs incurred by University on or after the Effective Date will be invoiced to Company and Company will pay amounts on such invoices within [***] of Company’s receipt of the applicable invoice.

  

	 	ii.	If Company fails to pay invoices for Patent Costs [***], then upon request by University, Company will make estimated advanced payments for Patent Costs. University will specify the amount of any such advanced payments
on an invoice provided to Company, identifying the applicable Licensed Patent, country and estimated cost. Company will pay such advance payments of Patent Costs to University prior to the relevant patent deadlines. Invoices for advanced payments
will be reconciled with the advance payments made by Company every [***]. Any excess payment by Company will be credited to future Patent Costs specified in this Section 6.B. 

 

	 	iii.	Notwithstanding any provisions to the contrary in this Agreement, if University does not receive, by the date specified, full payment for any Patent Costs, University may, at its sole discretion at any time, do any one
or more of the following: (a) without further notice to Company, abandon any Licensed Patent to which such payment applies and any related Licensed Patents, including any Licensed Patent that claims priority to such Licensed Patent; or
(b) notify Company that it is in breach of the Agreement for such failure to pay, in which case the terms of Section 7.B. shall apply. 

  

	 	iv.	Company may at any time, elect to discontinue its support of Patent Costs for one or more patent applications or patents within the Licensed Patent(s). If Company decides to discontinue its support of Patent Costs for
one or more patent applications or patents within the Licensed Patent(s), Company will notify University in writing [***] prior to any such discontinuation. Company will be responsible for reimbursing University for any Patent Costs associated with
such Licensed Patent(s) that University incurs in the [***] period following such notice, whether or not such costs were invoiced to University during such period; provided, University shall use reasonable efforts to mitigate such Patents Costs.

  

	 	v.	Upon Company’s election to discontinue support pursuant to Section 6.B.v or its failure to pay Patent Costs in accordance with Section B(ii) above for any Licensed Patents, all of Company’s rights in or
to the applicable Licensed Patents shall automatically terminate (regardless of whether Schedule A reflects such termination) and all rights to the applicable patent applications and patents will immediately revert to University. Without limiting
any other rights of University, University may in its sole discretion, abandon the applicable patent or patent application or license such patent or patent application to a third party at any time after such termination. If: 

  

					
	7805096	  	Page 18 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	(a)	University continues to prosecute and/or maintain any such former Licensed Patents, 

  

	 	(b)	Company has continued to support at least the European and United States counterparts of such formerly Licensed Patents, and 

  

	 	(c)	such formerly Licensed Patents have not been licensed by University to a third party, 

 for a
[***] period from the issuance of any such Licensed Patent, Company may elect to re-acquire its exclusive license to any such former Licensed Patent by paying to University before the end of the [***] period
both: 
  

	 	(d)	[***] of the Patent Costs incurred by University in the period following the termination of Company’s license to the applicable former Licensed Patent and 

 

	 	(e)	any Royalties that would have been owed for the sale of Licensed Products under the applicable Licensed Patent from the date of First Commercial Sale in the applicable territory. 

 

	 	C.	Challenges. If any Licensed Entity brings an action or proceeding, or assists any third party in bringing an action or proceeding, seeking a declaration or ruling that any claim in any of the Licensed Patents is
invalid or unenforceable, or asserts that any product or process does not infringe the Licensed Patents, then to the extent not prohibited by applicable law and in addition to, not in lieu of, other rights and remedies of University:

  

	 	i.	during the pendency of such action or proceeding, the Royalty rate applicable to payments made pursuant to Section 3.B.i with regard to Licensed Products covered by the Licensed Patent in suit will automatically
increase to [***] the royalty rate currently set forth in Section 3.B.i; 

  

	 	ii.	should the outcome of such action or proceeding determine that any claim of a Licensed Patent challenged is valid and enforceable, and the applicable Licensed Product is covered by the applicable Licensed Patent, then
the Royalty rate applicable to payments made pursuant to Section 3.B.i with regard to Licensed Products covered by the Licensed Patent in suit will automatically increase to [***] the royalty rate currently set forth in Section 3.B.i. and
Company will pay, if it had not already, University’s attorneys’ fees, expert witness fees, court costs, third party costs, and other litigation expenses incurred in connection with such action or proceeding; 

 

	 	iii.	For clarity, Company will have no right to recoup any Royalties or other amounts paid before such action or proceeding or during the period in which such action or proceeding is pending (including on appeal);

  

					
	7805096	  	Page 19 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	iv.	Company will continue to make all payments directly to University and will not, and will not seek to, pay into any escrow or other similar account; 

 

	 	v.	For clarity, University will have full control and authority to defend the Licensed Patents in such an action or proceeding; and 

  

	 	vi.	Company will provide written notice to University at least [***] before any Licensed Entity initiates any action or proceeding seeking a declaration or ruling that any claim of any Licensed Patent is invalid or
unenforceable or of its intention to assert that any product or process does not infringe any claim in the Licensed Patent. Company will include with such written notice an identification of all prior art it believes is material. 

 

	 	D.	Infringement. 

  

	 	i.	Notice. In the event either Party becomes aware of any possible or actual infringement, misappropriation, or other violation of any Licensed Patents in the Field in the Territory (an
“Infringement”), that Party will promptly notify the other Party and provide it with details regarding such Infringement. 

  

	 	ii.	 Company’s Right to Bring Infringement Action. Company will have the first right, but not the
obligation, to take action in the prosecution, prevention, or termination of any Infringement. Before Company commences an action with respect to any Infringement, Company will consider in good faith the views of University and potential effects on
the public interest in making its decision whether to sue. Company will keep University reasonably informed of the progress of the prosecution, prevention and/or termination of actions and will give University a reasonable opportunity in advance to
consult with Company and offer its views about major decisions. Company will give careful consideration to those views, but will have the right to control the action regarding Infringement; provided, however, that if Company fails to defend in good
faith the validity and/or enforceability of the Licensed Patents in the action, or if Company’s license to a Valid Claim in the suit terminates, then University may elect, but shall not be obligated, to take control of the action and any
recovery will be apportioned in the same manner as an action initiated by University pursuant to Section 6.D.iii. So long as Company controls any enforcement action, reasonable attorneys’ fees for counsel selected by University and out of
pocket expenses incurred by University in connection with the prosecution, prevention, termination, adjudication, and/or settlement regarding a Licensed Patent initiated by Company, including any related appeals, will be paid for by Company, and
Company will hold University free, clear and harmless from and against any and all such expenses. Any such expenses shall be paid out of any recovery. Notwithstanding any of the foregoing, Company will not compromise or settle any action involving
the Licensed Patents without the prior written consent of University, which consent will not be unreasonably withheld or delayed. In the event that Company controls the action pursuant to this Section 6.D.ii, it will first reimburse

  

					
	7805096	  	Page 20 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	
itself from any sums recovered in such suit or in settlement thereof for all out-of-pocket and documented costs and
expenses, including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such reimbursement, any funds remain, then such amounts shall be treated as Net Sales and shall be subject to Section 3.B.

  

	 	iii.	University’s Right to Bring Infringement Action. If Company does not take action in the prosecution, prevention, or termination of any Infringement pursuant to Section 6.D.ii above, and has not
commenced negotiations with the infringer for the discontinuance of said Infringement within [***] after it becomes aware of such Infringement or, at any time thereafter, ceases to diligently continue such prosecution, prevention, or termination,
University may elect, but is not obligated, to do so. Should University elect to bring suit against an infringer, Company will cooperate fully with University, including joining as party plaintiff in any such suit if requested by University. Company
will have the right to approve the counsel selected and paid for by University to represent University and Company, such approval not to be unreasonably withheld or delayed. In the event University exercises its right pursuant to this
Section 6.D.iii, it will recover for its own account any damages, awards or settlements. 

  

	 	iv.	Own Counsel. Each Party will always have the right to be represented by counsel of its own selection and at its own expense in any suit instituted by the other Party under this Section 6.D.

  

	 	v.	Cooperation. Each Party will cooperate fully in any action under this Section 6.D that is controlled by the other Party, provided that the controlling Party reimburses the cooperating Party promptly for any
costs and expenses incurred by the cooperating Party in connection with providing such assistance. 

  

	 	vi.	Declaratory Judgement. If a declaratory judgment action is brought alleging invalidity or unenforceability of any claims within the Licensed Patents, the Parties shall promptly notify the other, providing a copy
of the complaint, and Company will have the first right to control such action pursuant to Section 6.A. 

  

	 	vii.	Technical Information. University will have the exclusive right (but not the obligation), to the extent applicable, to institute legal action against any third party arising out of such third party’s actual
or threatened infringement or misappropriation of any Technical Information, and University will retain any and all proceeds from any such actions and settlements in connection therewith. Company will have no right to make any demands or claims,
bring suit, effect any settlements or take any other action with respect to any such infringement or misappropriation without the prior written consent of University. 

  

					
	7805096	  	Page 21 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	7.	Term and Termination 

  

	 	A.	Term. This Agreement and the rights and licenses hereunder will take effect on the Effective Date and will expire on a
country-by-country and Licensed Product-by-Licensed Product basis on the later of:
(i) the expiration date of the last to expire of the Licensed Patents covering the applicable Licensed Product in the applicable country; and (ii) fifteen (15) years from the First Commercial Sale, unless earlier terminated pursuant to the
terms of this Agreement. On a Licensed Product-by-Licensed Product basis, following the expiration of the Royalty obligations in a given country, Company shall retain
with respect to the Technical Information, a non-exclusive, fully paid, perpetual, irrevocable license, with the right to grant and authorize sublicenses, to make, have made, use, import, offer for sale and
sell such Licensed Product. 

  

	 	B.	University’s Right to Terminate. Without limiting other rights, University will have the right to terminate this Agreement as follows, in addition to all other available remedies: 

 

	 	i.	If Company fails to make any payment when due, this Agreement will terminate effective [***] after University’s written notice to Company describing such failure, unless Company makes such payment within such
[***]. 

  

	 	ii.	If Company breaches any material obligation of this Agreement other than an obligation to make a payment when due or a failure to perform the obligations in Section 4, this Agreement will terminate in its entirety,
effective [***] after University’s written notice to Company describing such material failure, unless Company cures such failure within such [***]; provided, in the event that Company disputes such material breach, no such termination shall be
effective until the matter has been finally resolved pursuant to Section 9.G. 

  

	 	iii.	If Company files, or has filed against it, a petition under any bankruptcy or insolvency law, Company will immediately notify University. If such petition is not dismissed within [***] of Company’s
filing, or if Company makes an assignment of all or substantially all of its assets for the benefit of its creditors, then, unless prohibited by applicable law, this Agreement will automatically terminate at the end of such [***] with respect to
Company unless University provides written notice to Company within such [***]. If Company becomes aware that any Licensed Entity is likely to become insolvent, it will notify University. 

 

	 	iv.	If Company will be dissolved, liquidated or otherwise ceases to exist, other than for reasons specified in Section 7.B.iv, unless prohibited by applicable law, this Agreement will automatically terminate with
respect to Company as of: (a) the date articles of dissolution or a similar document is filed on behalf of Company with the appropriate governmental authority; or (b) the date of establishment of a liquidating trust or other arrangement
for the winding up of the affairs of Company. 

  

					
	7805096	  	Page 22 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	C.	Termination and Affiliates. 

  

	 	i.	For the avoidance of doubt, if this Agreement expires or terminates for any reason, the rights and licenses granted to Company’s Affiliates hereunder will expire or terminate to the same extent as such rights and
licenses expire or terminate with respect to Company; provided if such Affiliates have become Sublicensees, such Sublicenses shall continue pursuant to Section 7.G (iii). 

 

	 	ii.	In the event that any entity ceases to be an Affiliate of Company, whether as the result of a sale, merger, corporate reorganization, or otherwise, the licenses granted to such entity pursuant to Section 2.A shall
automatically and immediately terminate. 

  

	 	D.	Company’s Right to Terminate. In the event Company desires to terminate this Agreement in its entirety, or as to any country or any Licensed Patent or Technical Information, Company will provide written
notice to University thereof and this Agreement shall terminate with respect to the applicable country or Licensed Patent or Technical Information [***] thereafter. 

 

	 	E.	Survival. The rights and obligations accruing prior to any termination or expiration of this Agreement for any reason will survive, including: (i) all causes of action accruing to either Party under this
Agreement; (ii) Company’s obligation to pay amounts payable under this Agreement accrued prior to the date of termination or expiration, including Royalties and Patent Costs; (iii) Company’s obligation to report Net Sales and
keep records, as required by Sections 3.E and 5; (iv) University’s right to audit under Section 5.A; (v) any obligation to abate an Infringement that arose prior to the date of termination or expiration under Section 6; and
(vi) Sections 5 (records and review), 7.E (survival), 7.F (post-termination obligations of Company), 8 (representations and warranties), and 9 (miscellaneous) of this Agreement until their purposes are fulfilled. 

 

	 	F.	 Post Termination, Post Expiration Obligations of Company. Upon the termination of this Agreement for any
reason, subject to the terms of Section 7.G., all rights of Company to use the Licensed Patent(s) and Technical Information will immediately thereafter cease and revert to University and Company will not practice the Licensed Patents or
Technical Information. Except to the extent set forth in Section 7.E, any other rights conferred to Company by this Agreement will also immediately thereafter cease. Except as necessary to comply with applicable laws, regulations, or the terms
and conditions of this Agreement, promptly following the termination of this Agreement, Company will, and will cause all other Licensed Entities to, deliver to University, or at University’s request irretrievably destroy, all tangible materials
embodying or relating to any unexpired Licensed Patents or any Technical Information; provided, however, Company shall have no obligation to destroy or seek to destroy electronic records (e.g., backup files) maintained for archival purposes that may
retain Technical Information. Company will provide to University a certification that such delivery or destruction has been completed. Company will not thereafter operate or conduct business in any manner that might tend to

  

					
	7805096	  	Page 23 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	
create the impression that this Agreement is still in force, or that Company has any right to use any one or more of Licensed Patents or Technical Information. Upon termination or expiration, all
payments including fees and costs due under this Agreement and not yet paid will become immediately due and payable. 

  

	 	G.	Consequences of Termination. 

  

	 	i.	Accrued Rights and Obligations. Expiration or termination of this Agreement for any reason shall not affect either Party’s rights or obligations accrued to such Party as of the effective date of termination
or based upon any event occurring prior to the effective date of termination. 

  

	 	ii.	Stock on Hand. In the event this Agreement is terminated for any reason, Company shall have the right to sell or otherwise dispose of all Licensed Products in the process of manufacture, testing, in use or in
stock, provided that Company shall remain obligated to make payment of Royalties to University for such Licensed Products in accordance with Section 3.B. 

  

	 	iii.	Sublicenses. In the event this Agreement is terminated pursuant to Section 7.B.iii or iv, [***]. 

  

	8.	Representations, Warranties, Disclaimers; Indemnification; Insurance; Primary Responsibility 

  

	 	A.	Representations, Warranties and Covenants of Company. Company hereby represents, warrants and covenants that: 

  

	 	i.	Company is a corporation duly organized, validly existing and in good standing under the laws of Delaware, has the corporate power and authority to execute and deliver this Agreement, including on behalf of its
Affiliates, and perform all obligations under this Agreement. 

  

	 	ii.	The execution, delivery and performance have been duly and validly authorized by Company, and upon execution and delivery by Company, this Agreement will constitute a valid, enforceable and binding agreement of Company
and of its Affiliates. 

  

	 	iii.	Company has no other agreements that conflict with the obligations undertaken and rights and licenses granted in this Agreement. 

  

	 	iv.	Company will comply and require all other Licensed Entities to comply with applicable laws, including to ensure that any manufacture of Licensed Product(s) by a Licensed Entity, and/or its respective vendor(s),
suppliers agents or contractors, will comply with and conform with applicable law and to all applicable specifications required by any regulatory body and/or market approval granted. 

  

					
	7805096	  	Page 24 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	v.	No Licensed Entity will take any action or engage in any activity that substantially increases the risk that any Licensed Patent is likely to be found invalid or unenforceable. 

 

	 	vi.	Company will make all payments to University as and when required by this Agreement. 

  

	 	B.	Representations, Warranties and Covenants of University. University represents and warrants that, to the knowledge of the University Personnel: 

 

	 	i.	it is a not-for-profit corporation duly organized validly existing and in good standing under the laws of Illinois; 

 

	 	ii.	the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of University; 

 

	 	iii.	to the actual knowledge of the personnel in the University’s Center for Technology Development and Ventures (UChicagoTech), University is the sole and exclusive owner of all right, title and interest in and to the
Licensed Patents, and all named inventors on the Licensed Patents have assigned to the University their entire right, title and interest in the applicable Licensed Patents; and 

 

	 	iv.	it has not previously granted and will not grant during the term of this Agreement, any right, license or interest in or to the Licensed Patents, or any portion thereof, inconsistent with the licenses granted to the
Company in this Agreement. 

  

	C.	Disclaimer of Warranties. EXCEPT AS EXPRESSLY PROVIDED IN SECTION 8.B., THE LICENSED PATENTS AND TECHNICAL INFORMATION ARE PROVIDED AS IS AND WHERE IS. UNIVERSITY MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY
KIND, WHETHER EXPRESS, STATUTORY, IMPLIED OR OTHERWISE. IN PARTICULAR, UNIVERSITY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, INCLUDING ABOUT (I) THE VALIDITY, SCOPE OR ENFORCEABILITY OF ANY OF THE LICENSED PATENTS; (II) THE ACCURACY,
SAFETY OR USEFULNESS FOR ANY PURPOSE OF ANY INFORMATION PROVIDED BY UNIVERSITY TO ANY LICENSED ENTITY; (III) FURNISHING ANY TECHNICAL INFORMATION; (IV) WHETHER THE PRACTICE OF ANY CLAIM CONTAINED IN ANY OF THE LICENSED PATENTS OR TECHNICAL
INFORMATION WILL OR MIGHT INFRINGE INTELLECTUAL PROPERTY RIGHTS ; (V) THE PATENTABILITY OF ANY INVENTION CLAIMED IN THE LICENSED PATENTS; (VI) THE ACCURACY, SAFETY, OR USEFULNESS FOR ANY PURPOSE OF ANY PRODUCT OR PROCESS MADE OR CARRIED OUT IN
ACCORDANCE WITH OR THROUGH THE USE OF THE LICENSED PATENTS; AND (VII) ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  

					
	7805096	  	Page 25 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	D.	Indemnification. Company agrees, and will cause each other Licensed Entity, to indemnify, defend and hold harmless University, its Affiliates and the trustees, directors, officers, students, employees, fellows
and agents of any of the foregoing (collectively the “Indemnified Persons”) from and against any and all third party claims, demands, liabilities, losses, damages, penalties, costs and/or expense (including attorneys’ and
witnesses’ fees and court costs) of any kind or nature, based upon, arising out of, or otherwise relating to this Agreement and/or a Sublicense, including without limitation (i) any claim arising from the development, production, use,
sale, export, import or other disposition of any Licensed Product and all activities associated therewith, or (ii) any use of information provided by University to any Licensed Entity. Company agrees, and will cause each other Licensed Entity
to agree, not to sue any Indemnified Person in connection with the development, production, use, sale or other disposition of Licensed Products and all activities associated therewith. University shall promptly notify Company of any claim or action
that may be subject to this Section 8.D., provide to Company a full description of all relevant facts, and cooperate fully with Company in the defense of any such action. Company shall control any legal proceeding subject to this
Section 8, provided; provided, however, that University’s failure to promptly notify Company shall only relieve Company of its obligations under this Section to the extent Company is actually prejudiced by such failure. University will be
entitled to participate, at its option and expense, through counsel of its own selection, and may join in any legal actions related to any such claims, demands, losses, damages, costs, expenses and penalties. No Licensed Entity will enter into any
settlement affecting any rights or obligations of any Indemnified Person or which includes an express or implied admission of liability, negligence or wrongdoing by any Indemnified Person, without the prior written consent of such Indemnified
Person. 

  

	E.	Assumption of Risk. The entire risk as to the performance, safety and efficacy of any subject matter claimed in any Licensed Patent, the Technical Information and of any Licensed Product is assumed by the Company
on behalf of the Licensed Entities. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, UNIVERSITY WILL NOT BE LIABLE TO ANY LICENSED ENTITY OR ANY OTHER PERSON OR ENTITY FOR INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE
OR ANY OTHER DAMAGES OR LOSSES OF ANY KIND OR NATURE, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), PRODUCTS OR STRICT LIABILITY OR ANY OTHER FORM OF ACTION; AND IN NO EVENT WILL UNIVERSITY’S TOTAL AGGREGATE LIABILITY UNDER OR IN CONNECTION
WITH THIS AGREEMENT TO ALL LICENSED ENTITIES AND OTHER PERSONS AND ENTITIES EXCEED THE TOTAL AMOUNTS PAID BY COMPANY TO UNIVERSITY HEREUNDER. The above limitations on liability apply even though the Indemnified Person may have been advised of the
possibility of such injury, loss or damage. Company will not, and will cause all other Licensed Entities not to, make any agreements, statements, representations or warranties or accept any liabilities or responsibilities whatsoever with regard to
any person or entity which are inconsistent with this Section 8.E. 

  

					
	7805096	  	Page 26 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	F.	Insurance. Company agrees, and will cause each other Licensed Entity to agree to continuously maintain during the term of this Agreement and beyond liability insurance that will cover its obligations hereunder,
including any claims for bodily injury, property, or other damage alleged to relate to Licensed Products or activities undertaken in connection with this Agreement, Licensed Patents, or Licensed Products, including the development, manufacture, use,
sale or other disposition of Licensed Products and all activities associated therewith. Each Licensed Entity will list University and its Affiliates, at such Licensed Entity’s expense, as additional named insureds under each liability insurance
policy (including excess or umbrella liability policies) that such Licensed Entity has or will obtain, that includes any coverage of claims relating to Licensed Products. Such insurance will be primary and noncontributory to any insurance University
and its Affiliates may have. At University’s request, Company will supply University from time to time with copies of each such policy, and will notify University in writing at least [***] prior to any termination of or change in coverage under
any such policies. 

  

	9.	Miscellaneous 

  

	 	A.	Marking. Company will mark all Licensed Products (or their packaging, as appropriate) sold, offered for sale, imported, or otherwise disposed of in such a manner not inconsistent with the requirements of the
patent laws and practices of the country to which such products are shipped or in which such products are manufactured or sold, including, if in the U.S., 35 U.S.C. § 287. 

 

	 	B.	Export Regulations. Without limiting Section 8.A, Company will comply with United States export control and asset control laws, regulations, and orders, as they may be amended from time to
time, applicable to the export, re-export, or import of goods or services, including software, processes, or technical data to foreign countries. Such regulations include but are not limited to the
International Traffic in Arms Regulations (22 C.F.R. § 120 et seq.), the Export Administration Regulations (15 C.F.R. § 730 et seq.), the regulations administered by the Treasury Department’s Office of Foreign Assets
Control (31 C.F.R. § 500 et seq.), and the Anti-Boycott Regulations (15 C.F.R. § 760). 

  

	 	C.	Entire Agreement, Amendment. This Agreement together with the schedules attached hereto constitutes the entire agreement between the Parties regarding the subject matter hereof, and supersedes all prior written
or oral agreements or understandings (express or implied) between them concerning the same subject matter. In entering into this Agreement, no Party has relied upon another person’s statement, representation, warranty or agreement except for
those expressly contained in this Agreement. The only conditions precedent to this Agreement’s effectiveness are those expressly stated in it. This Agreement cannot be amended or modified except in a document signed by duly authorized
representatives of each Party. 

  

					
	7805096	  	Page 27 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	D.	Notice. Any notice required or otherwise made under this Agreement will be in writing, sent by registered or certified mail properly addressed, or by facsimile with confirmed answer-back, to the other Party at
the address set forth below or at such other address as may be designated by written notice to the other Party. Notice will be deemed effective three (3) business days following the date of sending such notice if by mail, on the day following
deposit with an overnight courier, if sent by overnight courier, or upon confirmed answer-back if by facsimile. 

  

	 	If to University:	UChicagoTech 

	 	  	Center for Technology Development & Ventures 

	 	  	The University of Chicago 

	 	  	Edelstone Center, 2S 

	 	  	6030 S. Ellis Ave 

	 	  	Chicago, Illinois 60637 

  

	 	  	Facsimile Number: [***] 

	 	  	Attention: [***] 

  

	 	If to Company:	Evelo Biosciences, Inc. 

	 	  	Legal Department 

	 	  	620 Memorial Drive, Suite 200 

	 	  	Cambridge, Massachusetts 02139 

  

	 	  	Facsimile Number: [***] 

	 	  	Attention: [***] 

  

	 	E.	Assignment. This Agreement will be binding on the Parties and upon their respective successors and assigns and inure to the benefit of the Parties and their respective permitted successors and assigns.

 Company may at any time, upon written notice to University, assign or transfer this Agreement to (i) any Affiliate of
the Company, or (ii) a successor to all or substantially all of its business pertaining to this Agreement. Any such assignment will be conditioned on and will not be effective until the assignee or transferee has executed and delivered a
written agreement assuming and undertaking all of the duties and obligations of Company under this Agreement. Except as provided above, Company will not assign, transfer or delegate any right or obligation hereunder without the prior written consent
of University and any attempted conveyance in violation of any term of this Agreement will be null and void. University may assign or transfer this Agreement or its rights and obligations hereunder at any time to any third party on written notice to
Company. In the event of an assignment by University, the assignee will be substituted for University as a party hereto, and University will no longer be bound hereby. 

  

					
	7805096	  	Page 28 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	F.	Force Majeure. In the event either Party hereto is prevented from or delayed in the performance of any of its obligations hereunder by reason of acts of God, war, strikes, riots, storms, fires, earthquake, power
shortage or failure, failure of the transportation system, or any other cause whatsoever beyond the reasonable control of the Party (“Force Majeure Event”), the Party so prevented or delayed shall be excused from the performance of
any such obligation during a period that is reasonable in light of the Force Majeure Event, but no less than the duration of the Force Majeure Event itself. 

  

	 	G.	Governing Law. Illinois law (without regard to any jurisdiction’s conflict-of-laws principles) exclusively governs all matters
based upon, arising out of, or relating in any way to this Agreement, including, without limitation, all disputes, claims or causes of action arising out of or relating to this Agreement as well as the interpretation, construction, performance and
enforcement of this Agreement. The Parties will bring and litigate all actions or proceedings arising out of or relating to this Agreement in courts located within Chicago, Cook County, Illinois, and the Parties hereby consent to the jurisdiction of
such courts. Without limiting the foregoing, any dispute regarding the validity or enforceability of any of the Licensed Patents, or whether any product would infringe (but for this Agreement) any claim in the Licensed Patents, will be litigated
exclusively in the U.S. District Court for the Northern District of Illinois situated in Cook County, Illinois, and each Party will submit to the exclusive jurisdiction of such court, and waives any objection to venue, for such purposes.

  

	 	H.	Confidential Terms. Each Party agrees not to disclose to any Third Party the terms and conditions of this Agreement, without the prior approval of the other Party, except to advisors (including consultants,
financial advisors, attorneys and accountants), potential and existing investors, and others on a need to know basis, in each case under circumstances that reasonably protect the confidentiality thereof, or to the extent necessary to comply with the
terms of agreements with Third Parties, or to the extent required by applicable law, including securities laws. Each Party may issue press releases relating to this Agreement or activities conducted hereunder, provided that such Party shall submit
the text of such press releases to the other Party for its review prior to the issuance thereof. Both Parties may use information from any previous press release without having to submit such subsequent press release to the other Party.

  

	 	I.	Independent Contractors. The Company is an independent contractor under this Agreement. This Agreement does not, is not intended to, and will not be construed to, establish a partnership or joint venture, nor
does this Agreement create or establish an employment, agency or any other relationship. Company has no right, power or authority, nor will it represent itself or allow another Licensed Entity to represent itself as having any authority to assume,
create or incur any expense, liability or obligation, express or implied, on behalf of the University, or otherwise act as an agent for the University for any purpose. 

  

					
	7805096	  	Page 29 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	 	J.	No Use of Name. Neither Party will use (and Company will prohibit any Licensed Entity from using) the name, insignia, or symbols of University in any commercial activity, marketing, advertising or sales brochures
except with the prior written consent of the other Party, which consent may be granted or withheld at other Party’s sole discretion. Company agrees not to use, and will prohibit each other Licensed Entity from using, the name of any University
employee(s) in any commercial activity, marketing, advertising or sales brochures. 

  

	 	K.	Limitation of Liability. EXCEPT FOR EITHER PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 8, AND INDEMNIFICATION OBLIGATIONS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY
FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY, INCIDENTAL, STATUTORY OR PUNITIVE DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, OR THE SUBJECT MATTER HEREOF, WHETHER
SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

  

	 	L.	Waiver. No term or provision of this Agreement will be waived and no breach excused unless such waiver or consent is in writing and signed by the Party claimed to have waived or consented. No waiver of a breach
will be deemed to be a waiver of a different or subsequent breach. No delay in enforcing a term or provision will be deemed a waiver thereof. 

  

	 	M.	Construction. Each Party has consulted counsel of their choice regarding this Agreement, and each acknowledges and agrees that this Agreement will be construed without regard to the Party or Parties responsible
for the preparation of the same and will be deemed as prepared jointly by the Parties. Any ambiguity or uncertainty existing herein will not be interpreted or construed against any Party. No course of dealing, course of performance, or usage of
trade may be considered in the interpretation or enforcement of this Agreement. Both Parties waive any right they may have to introduce any such evidence. 

  

	 	N.	Execution. This Agreement may be executed by the Parties in any number of identical counterparts, each of which, for all purposes will be deemed to be an original, and all of which will constitute, collectively,
one instrument. 

  

	 	O.	Severability. If any provision of this Agreement is held to be invalid, illegal, unenforceable, or in conflict with any laws of any federal, provincial, state, or local government that may exercise jurisdiction
over this Agreement, the validity and enforceability of the remaining portions or provisions will not be affected thereby nor the validity and enforceability of such provision where valid, legal, enforceable and not in such a conflict. Any invalid
or unenforceable provision will be promptly reformed by the Parties to effectuate their intent as evidenced on the Effective Date. 

  

					
	7805096	  	Page 30 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 IN WITNESS WHEREOF, the Parties hereto have caused this agreement to be executed by their
respective duly authorized officers or representatives on the Effective Date. 
  

					
	University	 		  	Evelo Biosciences, Inc.
			
	 By: /s/ Alan Thomas
	 		  	 By: /s/ Simba Gill

	 Alan Thomas,
 Associate Vice President and
Director, UChicagoTech
	 		  	 Simba Gill,
 President & Chief
Executive Officer

			
	Date of signature: March 10, 2016	 		  	Date of signature: 10 March, 2016

  

					
	7805096	  	Page 31 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 Schedule A 

Licensed Patents 
  

									
	University
of Chicago
Reference
Number	  	Country	  	Application or
Patent
Number	  	Filing
or Issue
Date	  	 Title

	[***]	  	United States	  	#62/248,741	  	10/30/2015	  	Treatment of Cancer by Manipulation of Commensal Microflora
	[***]	  	United States	  	#62/169,112	  	6/01/2015	  	Treatment of Cancer by Manipulation of Commensal Microflora

  

					
	7805096	  	Page 32 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 Schedule B 

Technical Information 
 Characterization
of bacteria populations from [***] (other than Taconic and Jackson colonies) 
 Characterization of bacteria populations from [***] 

Analysis of bacterial genera [***] 

  

					
	7805096	  	Page 33 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 Schedule C 

UNIVERSITY OF CHICAGO ROYALTY REPORT 
  

					
	Company:
                                         
                                         
      	 		  	Agreement No:
                                         
                                
	Period Covered: From:
                                         
                       	 		  	Through:
                                         
                                         
   
	Prepared By:
                                         
                                         
 	 		  	Date:
                                         
                                         
          
	Approved By:
                                         
                                        	 		  	Date:
                                         
                                         
          

 Following First Commercial Sale of a second Licensed Product, please prepare a separate report for each. Then combine all
Licensed Products into a summary report. 
  

			
	Report Type:	  	 ☐ Single Product Line Report:
                                         
                                         
                                         
                              

		  	 ☐ Multiproduct Summary Report. Page 1 of _____ Pages

		  	 ☐ Product Line Detail. Line: __________     Tradename:
____________     Page: _____

	Report
 Currency:
	  	 ☐ U.S. Dollars     ☐
Other:
                                         
                                         
      

  

																									
	 Country
	 	Gross
Invoiced
Amount	 	 	* Less
Allowances	 	 	Net
Sales	 	 	Royalty
Rate	 	 	  

Period Royalty Amount
	 
	 	 	 	 	 	This Year	 	 	Last Year	 
	TOTAL:	 				 				 				 				 				 			

 Total Royalty:
                                    Conversion
Rate:                                Royalty in U.S. Dollars:
$                         

The following Royalty forecast is non-binding and for University’s internal planning purposes only: 

Royalty Forecast Under This Agreement: Next Quarter: _____    Q2: _____    Q3: _____    Q4: _____

  

					
	7805096	  	Page 34 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

	*	On a separate page, please indicate the reasons for returns or other adjustments if significant. Also, note any unusual occurrences that affected royalty amounts during this period. To assist University’s
forecasting, please comment on any significant expected trends in sales volume. 

  

					
	7805096	  	Page 35 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 Schedule D 

Product Development Plan 
 Subject to
reasonable revision based on data generated in development of Licensed Products, Company will: 
 1) Start First Human Testing by [***]. 

2) File for IND within [***] of Effective Date, if positive data from food study 

3) Begin clinical study with Intent to Treat Population greater than [***] or begin a Phase II trial within [***] of IND acceptance. 

  

					
	7805096	  	Page 36 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 Schedule E 

Progress Report Form 
 For the time period
_____________to ______________ regarding the Agreement, effective February __, 2016 between The University of Chicago and Evelo Biosciences UChicagoTech No. AGR 

UCHI No. [***] 
 Please fill out the fields below to the extent
that they are relevant. Any additional documents that may be helpful for illustration may be sent along as attachments. In some cases a conversation with University’s Center for Technology Development & Ventures ([***]) may be useful
as a follow-up. 
 Company Contact Name:__________________________ 

Company Contact Address & Phone:_________________ 

Summary 
 Accomplishments during this time period
regarding Licensed Products: 
 Objectives for the next time period regarding Licensed Products: 

Research & Development 
 Current status
of Licensed Products in development: 
 Plans for future research and development regarding Licensed Products: 

Products & Marketing 
 Licensed Products
launched (include tradenames) and estimate for time to the market for future Licensed Products: 
 Sales: 

  

					
	7805096	  	Page 37 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested Evelo Biosciences, Inc. 

FINAL 
  

 Projected sales: 

Market development: 

Sublicenses (If appropriate, have there been any new Sublicenses or progress in previous Sublicenses?): 

Industry News (mergers & acquisitions, development partnerships, company expansion, etc.) 

Financing & Corporate Development (non-dilutive capital, fundraising, diligence materials)

  

					
	7805096	  	Page 38 of 38	  	

 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]